



Agorastos, A., & Linthorst, A. C. E. (2016). Potential pleiotropic beneficial effects of adjuvant melatonergic treatment in posttraumatic stress disorder. *Journal of Pineal Research*, 61(1), 3-26. DOI: 10.1111/jpi.12330

Peer reviewed version

License (if available):  
CC BY-NC

Link to published version (if available):  
[10.1111/jpi.12330](https://doi.org/10.1111/jpi.12330)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at <http://dx.doi.org/10.1111/jpi.12330>.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/pure/about/ebr-terms.html>

## Potential pleiotropic beneficial effects of adjuvant melatonergic treatment in posttraumatic stress disorder

Agorastos Agorastos <sup>1\*</sup>, Astrid C. E. Linthorst <sup>2</sup>

<sup>1</sup> Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Germany.

<sup>2</sup> Neurobiology of Stress and Behaviour Research Group, School of Clinical Sciences, Faculty of Health Sciences, University of Bristol, United Kingdom.

**For publication in:** Journal of Pineal Research

**Article Type:** Review Article

**Running title:** Melatonin in PTSD

**Word count:** Main Text: 6,234 words  
(excl. references/legends)  
Abstract: 199 words

**Tables & Figures:** Tables: 0 Figures: 3

**Keywords:** Melatonin; circadian system; posttraumatic stress disorder (PTSD); stress; sleep; HPA axis; autonomic nervous system.

**\*Corresponding author:** Agorastos Agorastos, MD, Dr. med.  
Associate Professor  
Laboratory for Biological Psychiatry  
Dept. of Psychiatry and Psychotherapy  
University Medical Center Hamburg-Eppendorf  
Martini Str. 52, Bldg. W37, D-20246, Hamburg, Germany  
Tel.: ++49(0) 40 7410-52228  
Fax: ++49(0) 40 7410-59643  
Email: aagorast@uke.uni-hamburg.de

### **Abstract**

Loss of circadian rhythmicity fundamentally affects the neuroendocrine, immune and autonomic system, similar to chronic stress and may play a central role in the development of stress-related disorders. Recent articles have focused on the role of sleep and circadian disruption in the pathophysiology of posttraumatic stress disorder (PTSD), suggesting that chronodisruption plays a causal role in PTSD development. Direct and indirect human and animal PTSD research suggests circadian-system-linked neuroendocrine, immune, metabolic and autonomic dysregulation, linking circadian misalignment to PTSD pathophysiology. Recent experimental findings also support a specific role of the fundamental synchronizing pineal hormone melatonin in mechanisms of sleep, cognition and memory, metabolism, pain, neuroimmunomodulation, stress endocrinology and physiology, circadian gene expression, oxidative stress and epigenetics, all processes affected in PTSD. In the current paper, we review available literature underpinning a potentially beneficiary role of an add-on melatonergic treatment in PTSD pathophysiology and PTSD-related symptoms. The literature is presented as a narrative review, providing an overview on the most important and clinically relevant publications. We conclude that adjuvant melatonergic treatment could provide a potentially promising treatment strategy in the management of PTSD and especially PTSD-related syndromes and comorbidities. Rigorous pre-clinical and clinical studies are needed to validate this hypothesis.

## Introduction

The specific aim of this article is to review the available literature on a potentially beneficiary role of an adjuvant melatonergic treatment in PTSD, through restoring sleep and circadian alignment at different pathophysiological and molecular levels. For this scope, common neurobiological underpinnings of PTSD and circadian misalignment are outlined and human and animal research findings on melatonergic effects on different levels of the common pathophysiology are presented as a narrative review, providing an overview on the most important and clinically relevant publications.

### The human circadian system and melatonin

The human circadian system (CS) creates and maintains cellular and systemic rhythmicity, through temporal organization and coordination of many physiological and transcriptional processes in the organism [1, 2]. The human central CS includes the intrinsically photosensitive retinal ganglion cells (ipRGC), the retinohypothalamic tract, the suprachiasmatic nucleus (SCN), the superior cervical ganglia and the pineal gland (PGL) [2, 3]. The SCN is the primary pacemaker of the central CS, coordinating sleep and other physiological functions such as immune and autonomic activity, metabolism, neuroendocrine hormone secretion and thermoregulation via neuronal and humoral signals [1, 2, 4, 5]. Sleep homeostasis acts synergistically and bidirectionally with the central circadian system, but also independently restorative towards optimization of the internal temporal order [6]. Thereby, sleep onset and sleep stage timing are in particular associated with circadian gene expression in the SCN and thus tightly ruled by the CS [7]. Additionally, a peripheral oscillating network of partly independent orthologs and paralogs of the core CS components (peripheral *Zeitgebers*) orchestrates biological functions from the level of genetic variance and ubiquitously circadian gene expression to peripheral circadian oscillations [8-10]. The high complexity of this multi-oscillator system and the high number of external and internal rhythmicity-modulating factors enables numerous possibilities for interactions with different tissue-specific importance [10].

The major effector of the central CS is the PGL and its neurohormone melatonin [11]. Melatonin displays robust and predictable secretion rhythms, that synchronize numerous physiological processes in photoperiodic species [12, 13]. The time course of melatonin secretion from the pineal gland is strictly adapted to the circadian rhythm and controlled by the SCN through GABA-ergic inhibition reactive to a restricted bandwidth of visible light (460-480 nm, i.e. blue light) [12, 14]. Short-wavelength visible light in the blue-appearing portion of the spectrum is most potent for melatonin regulation than other action monochromatic light spectra [15]. The major route of melatonin delivery is the direct release into the cerebrospinal fluid (CSF) of the third ventricle assisted by a number of epithalamic structures (e.g., interpinealocyte canaliculi, evaginations of the posterodorsal third ventricle) [16]. Melatonin concentration reaches high levels at night and low levels during the day, with peak plasma levels between 0200 h and 0400 h, thus coinciding with decreases in core body temperature, alertness and performance [12, 13]. Melatonin exerts many peripheral physiological actions on cell-specific control by binding to the G-protein-coupled melatonin membrane receptors  $MT_1$  and  $MT_2$ . Furthermore, melatonin may interact with cytoplasmic factors (i.e. quinone-reductase-II/ $MT_3$  receptors, calmodulin) and nuclear receptors (i.e. retinoid acid receptor related orphan and Z receptors (ROR, RZR). Via these interactions, melatonin modulates peripheral oscillators and connected secondary molecular pathways, while numerous other actions of melatonin are receptor independent (e.g., radical scavenging – see also below) [10, 17-21] (*cf.* Figure 1). The sharp elevation of nocturnal CSF melatonin levels could also have substantial protective utility and be responsible for the sleep-specific tissue recovery after the daily free radical brain damage due to high oxygen utilization [16]. CSF melatonin protects the whole brain as it circulates through the aqueduct into the subarachnoid space surrounding the brain and penetrating into the deepest portions of the neural tissue where it diffuses into the neural parenchyma [16].

On the other hand, melatonin directly influences, in turn, SCN activity and central circadian “clock” mechanisms. Thereby, melatonin acts as a modulator of the electrical activity in SCN neurons through  $MT_1/MT_2$  [22, 23]. In addition, melatonin interacts with the

“clock” gene (Per1, Per2, Cry1, Cry2, clock, Bmal1, etc.) proteasome transcription loops in the SCN, thus modulating circadian rhythms and adjustment to environmental photoperiod changes [24]. These extremely multifaceted chronobiotic regulatory actions (see also below) have led to the recognition of melatonin as the most important natural substance modulating sleep and circadian rhythm [11-13, 17] and as one of the most pleiotropic biological signals in photoperiodic species [17, 25].

=====  
Please insert Figure 1 about here  
=====

### **Chronodisruption and stress**

This integrative system of complicated circadian hierarchy enables the interaction of circadian, hormonal, and metabolic systems towards an optimal homeodynamic state, physical health and environmental adaptation. In the last years, accumulating evidence outlines the importance of the human CS, melatonin and circadian-related factors in the maintenance of health. A critical loss of this time order at different organizational levels is defined as chronodisruption and introduces a breakdown of harmonious functioning internal biological systems and appropriate biobehavioral adaptation to external stimuli [26] with short and long-term molecular, pathophysiological and epigenetic impact [27]. Dysfunction of endogenous clocks, melatonin secretion and melatonergic signalling could, for example, contribute to altered gene expression and herewith to numerous physical and mental disorders [10].

Apart from inadequate exposure to the light-dark cycle (i.e. reduced exposure to sunlight during day, increased light exposure at night, natural light isolation), further both external and internal factors may also lead to a gradual shift or a total desynchronization of the CS. For example, acute and chronic physical, psychological, inflammatory and metabolic stress can affect the CS [28-32]. On the other hand, chronic circadian disruption may gradually change the fundamental properties of brain systems regulating neuroendocrine, immune and autonomic stress systems, similar to chronic stress [4]. Chronodisruption may,

thus, sensitize individuals to stress and increase vulnerability for stress-related disorders [33, 34].

### **Chronodisruption in posttraumatic stress disorder**

Posttraumatic stress disorder (PTSD) in DSM-V is classified as a trauma- and stress-related disorder with distinctive symptoms following a psychologically distressing event outside the range of usual human experience [35]. The estimated lifetime prevalence of PTSD in the general U.S. population lies between 5-6% in men and 10-14% in women [36]. Diagnostic criteria include current symptoms from each of four symptom clusters: intrusion, avoidance, negative alterations in cognitions and mood and alterations in arousal and reactivity including sleep disturbances. Sleep disturbances, especially, are prominent clinical features of PTSD, while there is evidence that sleep disruption after trauma may represent a core, rather than a secondary feature of PTSD and, thus, mediate the neurobiological correlates of the disorder through impaired homeostatic balance [37-40]. PTSD is characterized by a vast number of symptoms, co-morbid medical conditions and biological findings, also related to sleep deprivation (SD) and circadian disruption, suggesting that chronodisruption may represent a potential common underlying neurobiological link. Recent articles have focused on the role of chronodisruption in the pathophysiology of PTSD, suggesting that sleep and circadian dysregulation play a causal pathophysiological role in PTSD development [39-41] (*cf.* Figure 2). For example, disrupted melatonin levels in the first 48h after traumatic stress exposure were shown to be associated with a higher risk of PTSD development [42].

In this context, sleep and circadian regulation through exogenous circadian entrainment (e.g. melatonergic treatment) could play a central role in the prevention and treatment of PTSD. Nevertheless, relevant clinical literature is relatively sparse and mostly indirect. To date, the evidence-based recommendation for the first-line pharmacological treatment of PTSD includes only selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) [43].

=====  
Please insert Figure 2 about here  
=====

## **Melatonergic effects on PTSD-specific pathophysiological states and symptoms**

### **Sleep**

Stress is known to influence sleep physiology and dream patterns. Acute and chronic stress exposure may cause both immediate and long-lasting sleep disruption [38, 44, 45] which may, in turn, enhance maladaptive stress regulation [46]. Sleep disturbances are prominent clinical features of PTSD [37, 39], often resistant to first-line treatments [47-49] and closely related to higher PTSD psychopathology [50, 51], while their effective treatment is associated with significant improvement of overall PTSD psychopathology [52-54]. Sleep disturbances in PTSD are associated with sleep-related arousal regulation and other functions (i.e. dreaming, memory consolidation) [55] and include hyperarousal states, sleep avoidance and insomnia, nightmares, sleep terrors and nocturnal anxiety attacks, body-movement and breathing-related sleep disorders [37, 40, 56-58]. Most polysomnographic studies demonstrated heightened sympathovagal tone during rapid-eye-movement (REM) sleep using heart rate variability measures, as well as particularly fragmented REM sleep pattern and reduced REM theta activity in early-stage and sustained PTSD [39, 46, 55, 57-61]. On the other hand, REM sleep disruption in the immediate aftermath of a trauma has been associated with increased REM-related sympathetic activation, representing a major moderating and predictive factor in the development of PTSD [40, 62, 63]. Interestingly, there is also evidence that sleep impairment prior to traumatic stress exposure could contribute to PTSD vulnerability and development [64, 65]. These two studies both showed that reporting sleep complaints at baseline resulted in a 2.5-fold increased risk of fulfilling PTSD criteria 3 months after a trauma in general population admitted to a hospital or after deployment in active military troops respectively.

Sleep propensity and sleep rhythm regulation are temporally related to the SCN-controlled nocturnal rise in melatonin, which, in turn, exerts its hypnagogic and entraining action through MT<sub>1</sub> and MT<sub>2</sub> receptors of the SCN [23, 66, 67]. The different sleep stages are



also strongly circadian-bound and modulated by melatonin [68-70], thus suggesting that melatonergic effects may be beneficial for ameliorating sleep disruption and related disturbances. Numerous randomized-controlled trials (RCTs) and meta-analytic studies have repeatedly confirmed efficacy of exogenous melatonergic treatment. Melatonin and melatonergic agonists, when time-appropriately administered, are associated with significantly reduced sleep onset latency and increased sleep propensity, efficiency, quality and total sleep duration in patients with SD, such as insomnia [23, 67, 68, 71-75]. In addition, melatonergic treatment has been shown to lead to i) increased REM sleep percentage and continuity, normalization of sleep patterns and improvements in subjective measures of daytime dysfunction in neuropsychiatric patients with reduced REM sleep percentage or altered sleep patterns, ii) increased REM sleep percentage, advanced sleep/wake rhythm phase adjustment and sleep and wake-up propensity in healthy adults, as well as to iii) partial prevention of experimentally-induced REM suppression with pindolol in rats [67, 68, 70, 76]. Melatonergic treatment also shows a benign side-effect profile and safety in the short- and long-term administration, with no wearing-off in efficacy and without any withdrawal effects or dependence risk [23, 71, 74, 75, 77]. In addition, it has been proven also effective in the treatment of primary insomnia, circadian rhythm-related sleep-wake disorders, REM sleep behaviour disorders, body-movement and breathing-related sleep disorders, as well as in sleep disturbances within the scope of various psychiatric disorders (e.g., schizophrenia, depression) [72, 75, 76, 78-81]. Thus, melatonergic treatment could be an appropriate alternative for handling PTSD-specific sleep-related symptoms, while its implementation could even find use in PTSD prevention.

### **Circadian gene expression**

Molecularly, the biological clock is based on the transcriptional/translational feedback loop of clock genes, not limited to the SCN, but depending on its neuroendocrine/neuronal output [82]. Animal research provides evidence that circadian-related genes play a role in the neurobiological response to stress, while chronodisruption can lead to alterations in the

physiological oscillations of circadian-related gene expression in humans [83-86]. Animal research on PTSD and chronic mild stress models provides evidence that stress disrupts the regulated gene expression of circadian-related genes (e.g., Per 1, Per 2, Clock, Cry 1, Bmal 1, Npas 2) in several tissues including the hippocampus and the SCN [87-89]. Recently, a genome-wide association study showed that the retinoid-related orphan receptor alpha (RORA) gene, a clock gene, may represent a risk gene for PTSD [90].

Melatonergic regulation is known to adjust and reset amplitude and phase of CNS (e.g., SCN, hippocampus, pituitary pars tuberalis) and peripheral (e.g., adrenal gland) circadian-related gene transcriptional oscillation independently of previous phase [91-95]. In addition, immediate melatonergic treatment directly after exposure to predator scent stress, normalized the altered expression of Per 1 and Per 2 genes in hippocampal regions of rats, thus suggesting a possible immediate protective effect [88]. In addition, animal studies demonstrate a melatonergic regulation of peripheral clock genes oscillation in the adrenal gland and their responses to ACTH [91, 92, 96-98]. Melatonin is especially considered to play a partially moderating role in the circadian regulation of GR function (e.g. acetylation of GR, GR transcriptional activity, GC sensitivity, cell proliferation, etc.) [99-103], which is crucially involved in PTSD pathophysiology (see below).

### **Hypothalamic-pituitary-adrenal-axis and glucocorticoid signaling**

Hypothalamic-pituitary-adrenal (HPA) axis activity is closely linked to the CS and characterized by circadian rhythmicity [99, 104-106]. Through various pathways, the SCN and melatonin synchronize hypothalamic neuroendocrine neurons, influence adrenal sensitivity to adrenocorticotrophic hormone (ACTH), stimulate circadian glucocorticoid (GC) hormone secretion and interact with the own peripheral rhythm of the adrenal gland [99, 102, 107, 108]. Furthermore, cortisol and corticotropin-releasing hormone (CRH) are suggested to directly modulate PGL activity [29, 109, 110]. Interestingly, the phase angle between cortisol and melatonin onset has been identified as a potential useful biomarker in human stress-related research for distinguishing between healthy and depressed individuals [111].

Neuroendocrine findings in PTSD reveal increased central CRH levels, altered HPA axis reactivity with enhanced negative feedback inhibition and blunted circadian cortisol rhythm and cortisol awakening response (CAR), while some studies - but not all - have shown decreased circulating concentrations of cortisol [112-121]. An enhanced HPA axis negative-feedback sensitivity in PTSD is in line with an increased GC sensitivity and altered GC receptor (GR) responsiveness and density in different cell types in these patients [122-126]. Similar changes in HPA axis activity (e.g. reduced ACTH levels, increased CRH levels, increased/decreased cortisol levels) with altered endocrine reactivity to stressors (e.g., attenuated pituitary ACTH response, increased adrenocortical ACTH sensitivity) and blunted circadian cortisol rhythm and CAR have been also reported in patients with chronic insomnia, as well as in human and animal SD studies [33, 127-132], while pharmacological GR-antagonism has been found associated with insomnia symptoms improvement [133]. These similarities suggest that the HPA axis- and GC-signaling-specific alterations in PTSD may be partially mediated by sleep and circadian disruption [39, 134, 135].

Melatonin has been also shown to directly inhibit the adrenocorticotropin-stimulated cortisol production in the primate and human adrenal gland [97, 98]. In animal studies, chronic exogenous melatonergic treatment counteracts synthetic GC-induced dysregulation of the HPA axis. Melatonin has been shown to decrease hypothalamic CRH levels, to prevent the chronic stress-induced ACTH decline and to attenuate the adrenocortical secretory response in acute and chronic stress models [136-139].

### **Sympathoadrenal and autonomic nervous system**

The physiological fluctuations in circadian autonomic activity seen in humans are mainly modulated by the CS rhythms, through projections to pre-autonomic hypothalamic neurons responsible for cardiovascular autonomic control [140-142]. Chronodisruption is associated with increased sympathoadrenal activity and blunted autonomic and cardiovascular rhythmicity and responsiveness, constituting a major cardiovascular risk factor [33, 143]. PTSD patients exhibit similar autonomic findings such as hyperarousal, exaggerated startle

responses, increased basal heart rate and sympathovagal balance during day and night, increased autonomic responses to traumatic stimuli and norepinephrine levels, blunted autonomic diurnal rhythmicity and salivary alpha-amylase awakening response and overall reduced heart rate variability [63, 120, 144-150]. These findings suggest that chronodisruption-related chronic neuroautonomic dysregulation, could be responsible for the higher cardiovascular risk seen in this disorder. In particular, PTSD has been repeatedly associated with hypertension, cardiovascular diseases and myocardial infarctions and is increasingly considered an established risk factor for cardiovascular disease [151-156].

Melatonin has gradually gained interest as a potential cardioprotective and antihypertensive agent [157-159]. Apart from its antioxidant and scavenger properties reviewed below and its hypotensive effect, melatonin has been shown to centrally modulate autonomic nervous system (ANS) activity by inhibiting central sympatho-adreno-medullary (SAM) outflow and shifting autonomic balance in favour of vagal activity [141, 160-163]. In human and animal research, melatonin is shown to entrain disrupted autonomic rhythmicity and augment sympathoadrenal rhythm amplitude, reduce heart rate, norepinephrine levels, arousal and startle responsiveness, attenuate both orthostatic baroreflex and mental-stress-related sympathetic response and increase overall heart rate variability [140, 164-169]. As it is known that sympathetic activation of the paraventricular nucleus of the hypothalamus (PVN) inhibits melatonin secretion [5], restoring the autonomic imbalance seen in PTSD may also have reciprocal beneficial effects on the physiological melatonin secretion rhythm and as such further contribute to a reduction in PTSD symptoms.

### **Neuroimmunomodulation**

The CS and immune system are bi-directionally connected through intricate interactions between the autonomic nervous system and GC hormones influencing the expression of circadian genes and cytokine signaling [29, 170-176]. Immune system reactivity follows circadian rhythms imposed by the SCN and sleep synchronisation, whereas chronodisruption is associated with altered immune function, disarranged immunity-related activity rhythms

and inflammation [170, 177-180]. Chronic stress with impaired GC hormone signaling and chronic dysregulation of the HPA axis and SAM system also enhances chronic inflammation, immunosuppression and immunosenescence and could herewith contribute to accelerated biological aging and stress-related pathology of inflammatory-related medical conditions [113, 181-183]. Growing evidence concordantly associates PTSD with peripheral immune dysregulation and low-grade inflammatory excess state (higher IL-6, IL-1b, C-RP, TNF- $\alpha$  and lower IFN- $\gamma$  and IL-4 levels, lower lymphocyte counts, altered mononuclear and natural killer (NK) cell activity, etc.) [184-193], possibly involved in the overall increased morbidity rates seen in this disorder [194, 195]. Interestingly, low-grade inflammation even prior traumatic exposure has been also found to be a possible predisposing factor towards PTSD development [196].

Melatonin plays a fundamental role in the reciprocal relationship between the neuroendocrine and immune system [29, 170, 172, 173, 175, 176, 197-202]. Melatonin acts as an pluripotent immune regulator, immune-stimulating under basal or immunosuppressive conditions and immune-inhibiting in exacerbated immune responses [203]. It possesses numerous direct and indirect, as well as acute and chronic cellular and humoral immunomodulatory, antioxidative and anti-inflammatory properties both in vitro and in vivo [172, 200, 204-211]. Melatonin demonstrates endocrine, paracrine and autocrine effects in the leukocyte compartment, through modulation of pro-inflammatory enzymes, production of inflammatory mediators (i.e. cytokines, leukotrienes) and apoptotic processes [200, 211]. Melatonin also exerts important effects in cells of innate immunity [199]. Specifically, melatonin stimulates the production of granulocyte/macrophage progenitor cells, NK cells, CD4<sup>+</sup> cells and various cytokines from NK cells and T-lymphocytes, while limits cell migration [202, 212]. In addition, animal models suggest that melatonin counteracts negative immune effects of acute stress [213]. For example, in animal models, melatonin inhibits the endotoxin-induced increase in serum TNF- $\alpha$  levels, improves humoral and cell-mediated immune responses in GC-induced immunosuppression and restores metabolic-stress-induced elevated IL-1 $\beta$ , IL-6, TNF- $\alpha$ , IFN- $\gamma$  and CRP and reduced IL-4 and IL-10 levels [214-

217]. These properties suggest a central pleiotropic role of melatonin in physiological immune processes and immunosenescence and have placed melatonin among the newest promising agents in immunotherapy [211]. Of particular interest for cancer immunotherapy is the observation that melatonin causes synergistic effects with specific cytokines, which may lead to higher antitumoral activity and a lower incidence of side effects [204].

### **Metabolism**

The CS is closely connected with the regulating expression and activity of key players in cellular metabolism [143, 218]. Chronodisruption can lead to pro-orexic lipid and glucose metabolic alterations and consequently to related pathological metabolic conditions (e.g., diabetes, obesity, metabolic syndrome) [219-221]. PTSD and PTSD-related endocrine findings have been repeatedly associated with higher rates of metabolic clinical manifestations such as higher BMI and obesity, higher leptin and insulin levels with lower insulin sensitivity, and higher risk for metabolic syndrome, type-2 diabetes and dyslipidemia (higher total cholesterol, triglycerides, low-density lipoprotein-cholesterol and lower high-density lipoprotein-cholesterol) [222-228].

Melatonin is a major metabolic regulator and responsible for an adequate energy balance and mobilization [229]. Among other functions, melatonin regulates glucose homeostasis and proper synthesis, secretion, and action of insulin, plasma lipid profile, activation of brown adipose tissue, and the browning process of white adipose tissue. [230-232]. In experimental animal models, M melatonin LT reduces both adiposity and body weight, inhibits insulin release, increases insulin sensitivity and ameliorates the altered biochemical metabolic alterations seen in animals fed on a high-fat diet (e.g., dyslipidemia, oxidative stress) [216, 233, 234]. Similarly, in clinical human research, melatonin treatment has been proven beneficial in patients with metabolic syndrome, diabetes and peri-/postmenopausal women resulting in normalization of lipid profiles and reduced HbA1c levels [235-237]. Melatonin seems also efficacious in the prevention of drug-related metabolic side-

effects (e.g., weight gain, abdominal obesity, hypertriglyceridemia), as for example observed in patients treated with olanzapine [238].

### **Oxidative stress and traumatic brain injury**

Oxidative stress (OXS), defined as a disequilibrium between oxidant generation and antioxidant response, represents cellular chemical stress by an excess of free radicals (e.g., reactive oxygen species, ROS and reactive nitrogen species, RNS). OXS can be triggered by many exogenous (e.g., toxins, chemicals, UV-light, smoking) and endogenous (e.g., hyperglycemia, dyslipidemia, cytokines, chemokines) factors and deplete cellular defences, thus initiating inflammation [239, 240]. Free radicals from subcellular compartments lead to severe structural injuries and functional alterations of macromolecules, membranes, cellular organelles, as well as coding material (i.e. through lipid peroxidation or protein oxidation) [21, 239]. For example, telomere length decline, as a proxy for cellular aging, has been associated with OXS [241, 242].

OXS plays a major pathophysiological role in the development of many disorders, potentially including psychiatric and neurodegenerative conditions [239, 241]. The effects of early-life and traumatic stress on higher CNS and peripheral OXS-related marker levels have been investigated in animal models, but also clinical research. For example, early-life stress and PTSD have both been linked to shorter telomere length (a novel biomarker of accelerated cell aging and OXS) in clinical research [241, 243-245]. Respectively, higher levels of glutathione (a marker for neuronal OXS) were reported in dorsolateral prefrontal cortex and anterior cingulate cortex of PTSD patients using proton magnetic resonance spectroscopy [246]. These findings are supported by several animal PTSD-models reporting increased OXS markers and OXS-related metabolomic and transcriptomic effects in blood, adrenal gland, liver and CNS tissues compared to controls [246-248]. This line of evidence suggests that trauma-related stress, as seen in PTSD, potentiates OXS, thus modulating

neural integrity, accelerating cellular aging and increasing neuropsychiatric vulnerability [240, 249].

There is a large amount of data suggesting that melatonin exhibits distinct antioxidant characteristics and free radical scavenging properties, which has been also hypothesized to be the evolutionary initial and primary function of melatonin [20, 250]. Given its small molecular size and its amphipathic behaviour, melatonin efficiently protects every subcellular compartment against OXS through a variety of mechanisms [21]. Melatonin and its metabolites exert direct scavenging effects on ROS/RNS and radical products, reduce free radical formation by support of mitochondrial electron flux, induce redox and other antioxidant enzymes while suppressing pro-oxidant enzymes, contribute to the maintenance of membrane stability, protect mitochondrial DNA and homeostasis, reduce metal-induced toxicity through concurrent chelating cascades and finally induce defence mechanisms suppressing inflammation [20, 21, 211, 239, 242, 250-258]. Especially in stress-related research, animal models have shown that melatonin can effectively counteract OXS and neurodegeneration, suppress various apoptotic markers and ameliorate the oxidant effects of GCs induced by stressful conditions [259-262].

These facts appear even more important, when considering the correlation between traumatic brain injury (TBI) and PTSD. The pathogenesis of TBI is directly related to secondary biochemical cascades following injury and exacerbating primary damage, which result in the imbalance between oxidant agents and antioxidant defence and, thus, lead to OXS, excitotoxicity, ionic imbalances, cerebral edema, neuroinflammation, neural dysfunction and cell loss with functional impairment [263-265]. Both PTSD and TBI commonly occur in the general population but are especially comorbid in military populations [266, 267]. TBI shares overlapping pathophysiological pathways with PTSD (i.e., altered brain networks with reduced prefrontal function, volume loss in amygdala, etc.), leading to similar symptoms (e.g., cognitive impairment, sleep disruption) [268, 269] higher levels of PTSD symptomology [267, 270-272] and increased vulnerability to the disorder [270, 273-275]. Prospective studies have confirmed TBI as a major predictor of PTSD risk [276]. In



animal models of TBI, but also in human RCTs, melatonin has proven beneficial in preventing and ameliorating the effects of the neurotrauma, such as OXS, brain edema, and neuronal degeneration, as well as TBI-related functional impairment through its antioxidant, neuroprotective and antiapoptotic qualities [277-282]. Interestingly, TBI in rats has been found to cause increased DNA methylation and reduced expression of the *Aanat* gene [283], encoding serotonin N-acetyltransferase, one of the two enzymes involved in the synthesis of melatonin from serotonin.

### **Cognitive function, memory and neurocircuitry**

Both animal and human studies demonstrate cognitive performance being sensitive to the CS [284-286]. Cognitive performance as well as memory processing, formation and consolidation are directly influenced by the circadian clock, melatonin and the HPA axis [284-294]. Sleep promotes memory consolidation, particularly for emotionally salient information [285], while SD may reduce the connectivity between amygdala and PFC [295] and disrupt memory consolidation [296-300]. Accordingly, several studies have successfully replicated distinctive neuropsychological deficits (e.g. deficits in attention, learning & memory, executive function, decision making) in association to sleep disruption in humans [301-305].

Besides sleep disruption, acute and traumatic stress also affect neural correlates of memory formation [306-308]. PTSD is similarly associated with several cognitive deficits, crucial for the development and maintenance of the disorder [309-311] and in part directly related to sleep disturbances [312]. Specifically, impaired executive functioning, learning, cognitive information processing, free and cued recall, recognition and declarative memory performance, verbal memory, fear conditioning, fear extinction and explicit memory for emotional material have been repeatedly reported in patients with PTSD [311, 313-316]. Neuroimaging studies have reported hyporesponsive medial PFC regions, hyper-responsive amygdala and smaller hippocampal volume with decreased activation in patients with PTSD [310, 317-319]. These alterations are related to the impaired associations between contextual stimuli and aversive events, prediction errors during fear learning and extinction, disarranged regulation of negative emotion and fear gating by contextual information

reported in this disorder [320-323]. In addition, animal studies have put forth a significant impact of circadian rhythmicity on homeostasis, neurogenesis and neural activation in these exact brain regions [324-329].

Interestingly, research findings suggest a direct enhancing effect of melatonergic transmission in stimulus processing and memory consolidation, especially under stress [330-332]. In addition, in animal models melatonin has been associated with positive structural effects on synaptic plasticity and dendritic remodeling in cortical and hippocampal brain areas associated with cognitive and memory function, which may be caused by alterations in the regulation of cell adhesion molecules expression [93, 333]. Melatonin has also been shown to influence circadian clock gene expression in hippocampal neurons (see above) and to protect these neurons from oxidative stress, by preventing GC-related toxicity and inhibition of hippocampal neurogenesis and cell proliferation through decrease of receptor translocation to nuclei in models of SD and chronic stress [260, 334-336].

Melatonergic action has been shown to resemble sleep effects and prevent and/or reverse stress-, SD- and aging-related cognitive impairment and memory deterioration [334, 335, 337-340], as well as facilitate conditional cued fear extinction [341], without leading to next-day cognitive impairment, as seen with other hypnotics [342]. Reports suggest, that interventions aimed at restoring normal hippocampal function, disrupting dysfunctional aversive memories and enhancing extinction of conditional cued fear may serve future treatment strategies for PTSD [320, 341, 343].

## **Pain**

Chronic pain syndromes and hyperalgesia to nociceptive stimuli are often reported in PTSD and are also associated with trauma history without PTSD [344-347]. Chronic pain is also considered a form of chronic stress and has been associated with hypocortisolism and enhanced HPA axis negative-feedback sensitivity, similar to PTSD [348-354]. Pain modulation and nociception exerts circadian variations [355-357] and interacts bidirectionally with sleep and the CS, with SD leading to hyperalgetic states and acute or chronic pain to

sleep and chronodisruption [358-363]. In particular, pain modulation seems closely linked to melatonin, which acts direct or indirect through MT<sub>1</sub>, MT<sub>2</sub>,  $\mu$ -opioid, GABA<sub>B</sub> and NMDA receptors at spinal and supraspinal levels [364-368]. The analgetic effect of melatonin is supported by both experimental and clinical evidence. Animal research has confirmed dose-dependent, antinociceptive and analgetic effects of melatonin in acute, chronic and inflammatory pain models [369-371]. In clinical human research, endogenous melatonin secretion has been shown to be responsive to acute pain episodes [372], while exogenous M melatonin LT has shown analgesic, antihyperalgesic and antiallodynic efficacy in intra- and postoperative analgesia [373] and experimental pain studies [374], as well as in some, but not all studies of chronic pain syndromes (e.g., fibromyalgia, irritable bowel syndrome, endometriosis, migraine, neuropathic pain) [366, 369, 375-378]. Melatonergic treatment could, thus, represent a novel efficacious alternative treatment in patients with chronic pain comorbidity, such as PTSD patients [366, 367, 369, 379].

### **Epigenetics**

Epigenetic regulatory mechanisms at the chromatin, such as DNA (de-)methylation and histone modifications, act in concert bridging environmental and internal signals to modulate gene expression, thus resulting in transient as well as sustained transcriptional changes. Epigenetic modifications, as molecular consequences of stress and trauma experience, could play an important role in the aetiology of stress-related mental disorders and together with individual genetic predisposition explain disease susceptibility and stress resilience [380-383]. Early life events and childhood trauma are repeatedly shown to be associated with epigenetic changes and altered gene expression profiles especially in the CNS (e.g., hippocampus, amygdala), which influence stress responses and memory consolidation [382, 384-386]. For example, fear conditioning rodent models support the role of epigenetic regulation e.g. through stabilization of context- and cue-triggered fear conditioning [387, 388]. Moreover, subjecting rats to a an acute psychological stressful challenge has been shown to cause behavioral adaptations, which result from interactions between GR and the ERK1/2-

MSK1-Elk-1 signaling pathway leading to specific histone modifications in promoters of immediate early genes such as c-Fos and Egr-1 [389].

There is an increasing body of evidence in humans for gene programming and epigenetic regulation of specific genes in the pathophysiology of PTSD [388, 390-392]. Although there are no direct prospective findings on PTSD-specific epigenetic modifications, recent observations on the role of stress-related gene expression, early developmental influences and transgenerational effects are compatible with epigenetic explanations [393]. In particular, some GC-signaling related genes (e.g., GCR gene promoter 1F) are subject to stress- and trauma-related epigenetic regulation throughout life and may be useful as biomarkers associated with development, prognosis and symptom state of PTSD [394, 395].

The circadian machinery is highly involved in such epigenetic regulatory mechanisms, promoting specificity and seasonal/circadian plasticity of molecular environmental responses [396-398]. Epigenetic regulation utilizes to some extent highly sophisticated circadian transcriptional-translational feedback loops that modulate expression of cellular transcripts, while the circadian epigenome shares intimate links with chromatin remodelling (e.g., CLOCK protein has intrinsic histone acetyl transferase activity) [399].

Thereby, melatonin is particularly involved, modulating epigenetic processes in a circadian manner together with other epigenetic factors [239, 400-402]. Most importantly, melatonin is also suggested to exert direct beneficial effects in epigenetic regulation and protect from or even restore stress-related epigenetic changes [239, 401, 403-405]. In vitro, melatonin can regulate epigenetic modifications by both DNA methylation and histone modifications through its effects on nuclear receptors, co-regulators, histone acetylating enzymes and free radical scavenging [406-408]. Melatonin thus exerts prophylactic effects on the epigenome by decreasing gene-silencing related mRNA expression, inhibiting telomerase activity and significantly increasing chromatin remodeling (i.e. histone deacetylase isoforms, histone H3 acetylation activity) and gene transcription [406, 409].

## **Mood and anxiety**

Depression and anxiety disorders are highly comorbid psychiatric conditions in PTSD patients, which may share common risk factors and pathophysiological background [410, 411]. Most human research findings focus on the role of CS in depression, proposing that SD and chronodisruption are under-recognized but vital underlying mechanisms contributing to the development of mood disorders [412-415]. Several studies suggest, for example, an important role of circadian gene expression and polymorphisms in modulating reward motivation and active behaviour and, thus, determining mood disorders' susceptibility, recurrence and treatment response [413, 414, 416, 417]. A plethora of findings has also reported significant and acute negative effects on positive mood correlates in the aftermath of SD conditions in healthy people [418, 419]. Interestingly, studies in rats have shown that SD impacts on hippocampal serotonin and free GC hormone levels [420]. With respect to anxiety and anxiety disorders, evidence from human research has primarily focused on the relation between these conditions and SD [421, 422], while only relatively few studies examined circadian gene-related effects on anxiety-related behaviour [423, 424].

Although interventions able to resynchronize the human circadian system (i.e. SD, light therapy, etc.) have shown some potential in the treatment of depression [425, 426], there are no data unquestionably supporting the antidepressant efficacy of melatonin and melatonin receptor agonists [75, 427, 428], with the exception of agomelatine - a MT<sub>1</sub>/MT<sub>2</sub> agonist and 5-HT<sub>2C</sub> antagonist with antidepressant and anxiolytic potency [72, 429-432]. On the other hand, there is some evidence for (mostly acute) anxiolytic effects of melatonin and melatonin receptor agonists [431, 433]. Nevertheless, besides one single case-report on agomelatine treatment in PTSD, there is no clinical evidence for melatonin and melatonin receptor agonist effects in PTSD.

### **Further Co-morbidities**

Traumatic experience and PTSD are frequently related to several specific co-morbidities, such as chronic fatigue syndrome (CFS) [434-437], fibromyalgia [438-442], rheumatoid arthritis [443]. These syndromes share a very similar underlying neuroendocrinological profile

to PTSD (e.g., hypocortisolism, blunted diurnal cortisol rhythm and HPA axis reactivity) [444-449] and have all been repeatedly associated with evidence supporting circadian disruption [354, 450-459]. Interestingly, there is also relatively well-founded evidence for the efficacy of an adjuvant melatonergic treatment in these disorders. Several RCTs and open trials reported efficacy of melatonergic treatment with respect to the reduction of pain perception and sleep in fibromyalgia, as well as fatigue, concentration, motivation and activity in CFS, although there is only a small number of studies in general [377, 379, 460-465].

Similarly, traumatic stress experience and PTSD have been associated to an overall higher risk of cancer incidence, recurrence and mortality, partly in a dose-response manner [194, 195, 466-469]. Cancer biology has been intensively linked to the CS and chronodisruption [470-472], while melatonin has shown promising qualities as an oncostatic and adjuvant cancer treatment as there is evidence that melatonin can promote endocrine re-synchronization, tumor growth regression, stability of disease without tumor progression, as well as survival in cancer patients [473-477]. Melatonin reduces severe ROS and RNS-related DNA damage inducing cancer initiation and tumor progression [5, 6], controls tumor growth by activating signal transduction pathways, altering the expression of growth and differentiation-related genes [409, 478]. Melatonin is shown to upregulate the tumor suppressor gene GPC3, inhibit telomerase activity and endothelin-1 synthesis, inhibit COX-2 and p300 and downregulate cancer-related oncogenes (i.e. breast cancer EGR3 and POU4F2/Brn-3b) either by methylation of the Aromatase gene (CYP19) or deacetylation of CYP19 histones resulting in chromatin closing and binding inhibition of transcriptional factor triggering the expression of oncogenes [404, 409, 478-480]. A recent meta-analysis of RCTs confirmed the efficacy and safety of melatonin in cancer treatment [474], suggesting that melatonin is influential in inhibiting both cancer initiation and cancer cell growth.

## **Discussion**

Loss of circadian rhythmicity fundamentally affects the neuroendocrine, immune and autonomic system, similar to chronic stress and may play a central role in the development of

stress-related disorders. Disruption of sleep and of circadian rhythm after trauma represent core rather than secondary features of PTSD [37-40, 62, 63, 481] and are both a precipitating and perpetuating factor of the disorder [482-484]. Recent articles have focused on the role of the sleep and circadian disruption in the pathophysiology of posttraumatic stress disorder (PTSD), suggesting that chronodisruption plays a causal role in PTSD development. Circadian disruption could precipitate the neurobiological correlates of the disorder through impaired homeostatic balance with neuroendocrine, immune, metabolic and autonomic dysregulation, resulting in the extensive symptomatology and co-morbidity of PTSD [41, 151-155, 184, 443, 485-495].

Standard sleep pharmacotherapies in PTSD may treat sleep quantity sufficiently, but often fail to improve daytime functioning and restore the unique CS-related neurobiological changes in PTSD [6, 496]. Thus, the development of pharmacological interventions that would counteract changes in PTSD-related neurocircuitry and restore CS-related alterations could represent an interesting novel therapeutic strategy [413, 497-499]. Such pharmacotherapies could be incorporated into any standard PTSD treatment and be applied in addition to psychological-behavioral interventions, in cooperation with sleep specialists [61].

Melatonin is fundamental for circadian regulation and also plays a crucial role in several brain processes affected in PTSD. Recent experimental findings emphasize on the role of melatonin in mechanisms of sleep, cognition and memory, metabolism, pain, neuroimmunomodulation, stress endocrinology and physiology, circadian gene expression, oxidative stress and epigenetics. The efficacy of melatonin and melatonergic treatment beyond sleep regulation has been considered and investigated in numerous clinical conditions also found as comorbidities in PTSD, while most results confirm the very low toxicity and side-effects range of melatonin over a wide range of doses [78, 460, 500]. The hypnotic, rhythm resynchronizing, antioxidant, anti-inflammatory, antinociceptive, neuroprotective, pro-cognitive, metabolic, antiapoptotic and anxiolytic actions of melatonin and melatonergic agents could therefore represent a promising adjuvant contribution to the

clinical treatment and prevention of stress-related syndromes and comorbidities in mental disorders in general and PTSD in particular [10, 41, 499, 501-503] (*cf.* Figure 3).

=====  
Please insert Figure 3 about here  
=====

### **Conclusions**

Understanding the mechanisms susceptible to chronodisruption following trauma exposure and their role in a chronically dysregulated circadian network in PTSD could be valuable towards enabling innovative preventive strategies and psychochronobiological treatment possibilities in PTSD patients and high-risk trauma-exposed populations [8, 39, 58, 104, 504]. Unfortunately, relevant clinical literature is relatively sparse and regularly neglecting the potential effect of CS on the development of the pathophysiological findings in this disorder [57, 58, 114, 505]. Adjuvant melatonergic treatment could provide a potentially promising treatment strategy with beneficial effects in the treatment of PTSD and especially PTSD-related syndromes and comorbidities. This theoretical concept deserves thorough further investigation through pre-clinical research and clinical confirmation through RCTs assessing the efficacy of melatonin and melatonergic treatment in the prevention and treatment of PTSD.



**List of abbreviations**

ACTH	Adrenocorticotrophic Hormone
ANS	Autonomic Nervous System
CAR	Cortisol Awakening Response
CRH	Corticotropin-Releasing hormone
CS	Circadian System
CSF	Cerebrospinal Fluid
GC	Glucocorticoids
GR	Glucocorticoid Receptor
HPA axis	Hypothalamic-Pituitary-Adrenal axis
ipRGC	Intrinsically Photosensitive Retinal Ganglion Cells
MT <sub>1</sub>	G-protein-coupled Melatonin Membrane Receptor 1
MT <sub>2</sub>	G-protein-coupled Melatonin Membrane Receptor 2
NK cells	Natural Killer Cells
OXS	Oxidative Stress
PGL	Pineal Gland
PTSD	Posttraumatic Stress Disorder
PVN	Paraventricular Nucleus of the Hypothalamus
RZR	Receptor-related Z Receptor
RCT	Randomized Controlled Trial
REM	Rapid-Eye-Movement
RNS	Reactive Nitrogen Species
ROR	Receptor-related Orphan Receptor

RORA	Retinoid-related Orphan Receptor Alpha
ROS	Reactive Oxygen Species
SAM system	Sympatho-Adreno-Medullary System
SCN	Suprachiasmatic Nucleus
SD	Sleep Deprivation
SNRI	Serotonin-Norepinephrine Reuptake Inhibitors
SSRI	Selective Serotonin Reuptake Inhibitors
TBI	Traumatic Brain Injury

### **Acknowledgments**

This article is part of the European College of Neuropsychopharmacology (ECNP) Certificate Curriculum of AA.

### **Author Contributions**

AA conceptualized the paper, managed the literature searches and wrote the first draft of the paper. ACEL revised the draft and discussed the presented concepts with AA. Both authors have contributed to, read and approved the final version of the manuscript.

### **Conflicts of Interest**

AA and ACEL report no biomedical financial interests or potential conflicts of interest and none of the authors received funding for this article.

### References

1. MOORE RY. The suprachiasmatic nucleus and the circadian timing system. *Prog Mol Biol Transl Sci* 2013; 119:1-28.
2. SAPER CB. The central circadian timing system. *Curr Opin Neurobiol* 2013; 23:747-751.
3. BERSON DM, DUNN FA, TAKAO M. Phototransduction by retinal ganglion cells that set the circadian clock. *Science* 2002; 295:1070-1073.
4. MORRIS CJ, AESCHBACH D, SCHEER FAJL. Circadian system, sleep and endocrinology. *Mol Cell Endocrinol* 2012; 349:91-104.
5. BUIJS RM, VAN EDEN CG, GONCHARUK VD, et al. The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. *J Endocrinol* 2003; 177:17-26.
6. ZISAPEL N. Sleep and sleep disturbances: biological basis and clinical implications. *Cell Mol Life Sci* 2007; 64:1174-1186.
7. LEE ML, SWANSON BE, DE LA IGLESIA HO. Circadian timing of REM sleep is coupled to an oscillator within the dorsomedial suprachiasmatic nucleus. *Curr Biol* 2009; 19:848-852.
8. ROENNEBERG T, MERROW M. The network of time: understanding the molecular circadian system. *Curr Biol* 2003; 13:R198-207.
9. WEINERT D. Ontogenetic development of the mammalian circadian system. *Chronobiol Int* 2005; 22:179-205.

10. HARDELAND R, MADRID JA, TAN DX, et al. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. *J Pineal Res* 2012; 52:139-166.
11. MACCHI MM, BRUCE JN. Human pineal physiology and functional significance of melatonin. *Front Neuroendocrinol* 2004; 25:177-195.
12. ARENDT J. Melatonin and human rhythms. *Chronobiol Int* 2006; 23:21-37.
13. ARENDT J. Importance and relevance of melatonin to human biological rhythms. *J Neuroendocrinol* 2003; 15:427-431.
14. FIGUEIRO MG, REA MS. The effects of red and blue lights on circadian variations in cortisol, alpha amylase, and melatonin. *Int J Endocrinol* 2010; 2010:829351.
15. BRAINARD GC, HANIFIN JP, WARFIELD B, et al. Short-wavelength enrichment of polychromatic light enhances human melatonin suppression potency. *J Pineal Res* 2015; 58:352-361.
16. REITER RJ, TAN DX, KIM SJ, et al. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. *Brain Struct Funct* 2014; 219:1873-1887.
17. HARDELAND R, CARDINALI DP, SRINIVASAN V, et al. Melatonin--a pleiotropic, orchestrating regulator molecule. *Prog Neurobiol* 2011; 93:350-384.
18. REITER RJ, TAN DX, GALANO A. Melatonin: exceeding expectations. *Physiology* 2014; 29:325-333.
19. SLOMINSKI RM, REITER RJ, SCHLABRITZ-LOUTSEVITCH N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. *Mol Cell Endocrinol* 2012; 351:152-166.
20. MANCHESTER LC, COTO-MONTES A, BOGA JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. *J Pineal Res* 2015; 59:403-419.
21. GARCIA JJ, LOPEZ-PINGARRON L, ALMEIDA-SOUZA P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. *J Pineal Res* 2014; 56:225-237.
22. MASON R, BROOKS A. The electrophysiological effects of melatonin and a putative melatonin antagonist (N-acetyltryptamine) on rat suprachiasmatic neurones in vitro. *Neurosci Lett* 1988; 95:296-301.
23. SRINIVASAN V, PANDI-PERUMAL SR, TRAHKT I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. *Int J Neurosci* 2009; 119:821-846.
24. VRIEND J, REITER RJ. Melatonin feedback on clock genes: a theory involving the proteasome. *J Pineal Res* 2015; 58:1-11.
25. PANDI-PERUMAL SR, SRINIVASAN V, MAESTRONI GJ, et al. Melatonin: Nature's most versatile biological signal? *Febs J* 2006; 273:2813-2838.

26. ERREN TC, REITER RJ. Defining chronodisruption. *J Pineal Res* 2009; 46:245-247.
27. ZELINSKI EL, DEIBEL SH, MCDONALD RJ. The trouble with circadian clock dysfunction: Multiple deleterious effects on the brain and body. *Neurosci Biobehav Rev* 2014; 24:80-101.
28. GOGENUR I, OCAK U, ALTUNPINAR O, et al. Disturbances in melatonin, cortisol and core body temperature rhythms after major surgery. *World J Surg* 2007; 31:290-298.
29. COUTO-MORAES R, PALERMO-NETO J, MARKUS RP. The immune-pineal axis: stress as a modulator of pineal gland function. *Ann N Y Acad Sci* 2009; 1153:193-202.
30. CHRISTIANSEN S, BOUZINOVA EV, PALME R, et al. Circadian activity of the hypothalamic-pituitary-adrenal axis is differentially affected in the rat chronic mild stress model of depression. *Stress* 2012.
31. PAREDES SD, SANCHEZ S, PARVEZ H, et al. Altered circadian rhythms of corticosterone, melatonin, and phagocytic activity in response to stress in rats. *Neuro Endocrinol Lett* 2007; 28:489-495.
32. HARDELAND R, COTO-MONTES A, POEGGELER B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. *Chronobiol Int* 2003; 20:921-962.
33. MEERLO P, SGOIFO A, SUCHECKI D. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. *Sleep Med Rev* 2008; 12:197-210.
34. WEIBEL L, MACCARI S, VAN REETH O. Circadian clock functioning is linked to acute stress reactivity in rats. *J Biol Rhythms* 2002; 17:438-446.
35. AMERICAN PSYCHIATRIC ASSOCIATION. *Diagnostic and Statistical Manual of Mental Disorders*, 5th Edition. In, Washington DC, 2013.
36. YEHUDA R. Post-traumatic stress disorder. *N Engl J Med* 2002; 346:108-114.
37. SPOORMAKER VI, MONTGOMERY P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? *Sleep Med Rev* 2008; 12:169-184.
38. LAVIE P. Sleep disturbances in the wake of traumatic events. *N Engl J Med* 2001; 345:1825-1832.
39. GERMAIN A, BUYSSE DJ, NOFZINGER E. Sleep-specific mechanisms underlying posttraumatic stress disorder: integrative review and neurobiological hypotheses. *Sleep Med Rev* 2008; 12:185-195.
40. MELLMAN TA, HIPOLITO MM. Sleep disturbances in the aftermath of trauma and posttraumatic stress disorder. *CNS spectrums* 2006; 11:611-615.

41. AGORASTOS A, KELLNER M, BAKER DG, et al. When time stands still. An integrative review on the role of chronodisruption in PTSD. *Curr Opin Psychiatry* 2014; 27:385-392.
42. MCFARLANE AC, BARTON CA, BRIGGS N, et al. The relationship between urinary melatonin metabolite excretion and posttraumatic symptoms following traumatic injury. *J Affect Disord* 2010; 127:365-369.
43. BANDELOW B, ZOHAR J, HOLLANDER E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. *World J Biol Psychiatry* 2008; 9:248-312.
44. TOUMA C, FENZL T, RUSCHEL J, et al. Rhythmicity in mice selected for extremes in stress reactivity: behavioural, endocrine and sleep changes resembling endophenotypes of major depression. *PLoS One* 2009; 4:e4325.
45. PHILBERT J, PICHAT P, BEESKE S, et al. Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD). *Behav Brain Res* 2011; 221:149-154.
46. GERMAIN A. Sleep disturbances as the hallmark of PTSD: where are we now? *The Am J Psychiatry* 2013; 170:372-382.
47. ZAYFERT C, DEVIVA JC. Residual insomnia following cognitive behavioral therapy for PTSD. *J Trauma Stress* 2004; 17:69-73.
48. BELLEVILLE G, GUAY S, MARCHAND A. Persistence of sleep disturbances following cognitive-behavior therapy for posttraumatic stress disorder. *J Psychosom Res* 2011; 70:318-327.
49. SCHOENFELD FB, DEVIVA JC, MANBER R. Treatment of sleep disturbances in posttraumatic stress disorder: a review. *J Rehabil Res Dev* 2012; 49:729-752.
50. CLUM GA, NISHITH P, RESICK PA. Trauma-related sleep disturbance and self-reported physical health symptoms in treatment-seeking female rape victims. *J Nerv Mental Dis* 2001; 189:618-622.
51. NISHITH P, RESICK PA, MUESER KT. Sleep difficulties and alcohol use motives in female rape victims with posttraumatic stress disorder. *J Trauma Stress* 2001; 14:469-479.
52. KRAKOW B, HOLLIFIELD M, JOHNSTON L, et al. Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: a randomized controlled trial. *JAMA* 2001; 286:537-545.
53. RASKIND MA, PESKIND ER, KANTER ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. *Am J Psychiatry* 2003; 160:371-373.

54. GERMAIN A, SHEAR MK, HALL M, et al. Effects of a brief behavioral treatment for PTSD-related sleep disturbances: a pilot study. *Behav Res Ther* 2007; 45:627-632.
55. MELLMAN TA. Psychobiology of sleep disturbances in posttraumatic stress disorder. *Ann N Y Acad Sci* 1997; 821:142-149.
56. KRAKOW B, MELENDREZ D, PEDERSEN B, et al. Complex insomnia: insomnia and sleep-disordered breathing in a consecutive series of crime victims with nightmares and PTSD. *Biol Psychiatry* 2001; 49:948-953.
57. PILLAR G, MALHOTRA A, LAVIE P. Post-traumatic stress disorder and sleep-what a nightmare! *Sleep Med Rev* 2000; 4:183-200.
58. HARVEY AG, JONES C, SCHMIDT DA. Sleep and posttraumatic stress disorder: a review. *Clin Psychol Rev* 2003; 23:377-407.
59. NEYLAN TC, OTTE C, YEHUDA R, et al. Neuroendocrine regulation of sleep disturbances in PTSD. *Ann N Y Acad Sci* 2006; 1071:203-215.
60. KOBAYASHI I, BOARTS JM, DELAHANTY DL. Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. *Psychophysiology* 2007; 44:660-669.
61. LAMARCHE LJ, DE KONINCK J. Sleep disturbance in adults with posttraumatic stress disorder: a review. *J Clin Psychiatry* 2007; 68:1257-1270.
62. MELLMAN TA, BUSTAMANTE V, FINS AI, et al. REM sleep and the early development of posttraumatic stress disorder. *Am J Psychiatry* 2002; 159:1696-1701.
63. MELLMAN TA, KNORR BR, PIGEON WR, et al. Heart rate variability during sleep and the early development of posttraumatic stress disorder. *Biol Psychiatry* 2004; 55:953-956.
64. KOFFEL E, POLUSNY MA, ARBISI PA, et al. Pre-deployment daytime and nighttime sleep complaints as predictors of post-deployment PTSD and depression in National Guard troops. *J Anxiety Disord* 2013; 27:512-519.
65. BRYANT RA, CREAMER M, O'DONNELL M, et al. Sleep disturbance immediately prior to trauma predicts subsequent psychiatric disorder. *Sleep* 2010; 33:69-74.
66. DUBOCOVICH ML. Melatonin receptors: role on sleep and circadian rhythm regulation. *Sleep Med* 2007; 8 Suppl 3:34-42.
67. PANDI-PERUMAL SR, SRINIVASAN V, SPENCE DW, et al. Role of the melatonin system in the control of sleep: therapeutic implications. *CNS Drugs* 2007; 21:995-1018.
68. DIJK DJ, CAJOCHEN C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. *J Biol Rhythms* 1997; 12:627-635.

69. RAJARATNAM SM, MIDDLETON B, STONE BM, et al. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. *J Physiol* 2004; 561:339-351.
70. KUNZ D, MAHLBERG R, MULLER C, et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. *J Clin Endocrinol Metab* 2004; 89:128-134.
71. BRZEZINSKI A, VANGEL MG, WURTMAN RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. *Sleep Med Rev* 2005; 9:41-50.
72. CARDINALI DP, SRINIVASAN V, BRZEZINSKI A, et al. Melatonin and its analogs in insomnia and depression. *J Pineal Res* 2011.
73. KURIYAMA A, HONDA M, HAYASHINO Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. *Sleep Med* 2014; 15:385-392.
74. FERRACIOLI-ODA E, QAWASMI A, BLOCH MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. *PLoS One* 2013; 8:e63773.
75. SRINIVASAN V, BRZEZINSKI A, PANDI-PERUMAL SR, et al. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? *Prog Neuropsychopharmacol Biol Psychiatry* 2011; 35:913-923.
76. ARENDT J. Melatonin: characteristics, concerns, and prospects. *J Biol Rhythms* 2005; 20:291-303.
77. BUSCEMI N, VANDERMEER B, HOOTON N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. *J Gen Intern Med* 2005; 20:1151-1158.
78. LAUDON M, FRYDMAN-MAROM A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. *Int J Mol Sci* 2014; 15:15924-15950.
79. SHAMIR E, LAUDON M, BARAK Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. *J Clin Psychiatry* 2000; 61:373-377.
80. MCGRANE IR, LEUNG JG, ST LOUIS EK, et al. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. *Sleep Med* 2015; 16:19-26.
81. NUNES DM, MOTA RM, MACHADO MO, et al. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. *Braz J Med Biol Res* 2008; 41:926-931.
82. VON GALL C, WEAVER DR, MOEK J, et al. Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. *Ann N Y Acad Sci* 2005; 1040:508-511.
83. BRACCI M, MANZELLA N, COPERTARO A, et al. Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-beta-estradiol levels. *Scand J Work Environ Health* 2014.



84. FONKEN LK, AUBRECHT TG, MELENDEZ-FERNANDEZ OH, et al. Dim light at night disrupts molecular circadian rhythms and increases body weight. *J Biol Rhythms* 2013; 28:262-271.
85. ACKERMANN K, PLOMP R, LAO O, et al. Effect of sleep deprivation on rhythms of clock gene expression and melatonin in humans. *Chronobiol Int* 2013; 30:901-909.
86. MOLLER-LEVET CS, ARCHER SN, BUCCA G, et al. Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. *Proc Natl Acad Sci U S A* 2013; 110:E1132-1141.
87. TAKAHASHI K, YAMADA T, TSUKITA S, et al. Chronic mild stress alters circadian expressions of molecular clock genes in the liver. *Am J Physiol Endocrinol Metab* 2013; 304:E301-309.
88. KORESH O, KOZLOVSKY N, KAPLAN Z, et al. The long-term abnormalities in circadian expression of Period 1 and Period 2 genes in response to stress is normalized by agomelatine administered immediately after exposure. *Eur Neuropsychopharmacol* 2012; 22:205-221.
89. WEBER GF, JOHNSON BN, YAMAMOTO BK, et al. Effects of Stress and MDMA on Hippocampal Gene Expression. *Biomed Res Int* 2014; 2014:141396.
90. LOGUE MW, BALDWIN C, GUFFANTI G, et al. A genome-wide association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus. *Mol Psychiatry* 2013; 18:937-942.
91. VALENZUELA FJ, TORRES-FARFAN C, RICHTER HG, et al. Clock gene expression in adult primate suprachiasmatic nuclei and adrenal: is the adrenal a peripheral clock responsive to melatonin? *Endocrinology* 2008; 149:1454-1461.
92. RICHTER HG, TORRES-FARFAN C, GARCIA-SESNICH J, et al. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland. *Endocrinology* 2008; 149:995-1003.
93. IKENO T, NELSON RJ. Acute melatonin treatment alters dendritic morphology and circadian clock gene expression in the hippocampus of Siberian Hamsters. *Hippocampus* 2015; 25:142-148.
94. NAGY AD, IWAMOTO A, KAWAI M, et al. Melatonin adjusts the expression pattern of clock genes in the suprachiasmatic nucleus and induces antidepressant-like effect in a mouse model of seasonal affective disorder. *Chronobiol Int* 2014:1-11.
95. JOHNSTON JD, TOURNIER BB, ANDERSSON H, et al. Multiple effects of melatonin on rhythmic clock gene expression in the mammalian pars tuberalis. *Endocrinology* 2006; 147:959-965.

96. TORRES-FARFAN C, MENDEZ N, ABARZUA-CATALAN L, et al. A circadian clock entrained by melatonin is ticking in the rat fetal adrenal. *Endocrinology* 2011; 152:1891-1900.
97. TORRES-FARFAN C, RICHTER HG, ROJAS-GARCIA P, et al. mt1 Melatonin receptor in the primate adrenal gland: inhibition of adrenocorticotropin-stimulated cortisol production by melatonin. *J Clin Endocrinol Metab* 2003; 88:450-458.
98. CAMPINO C, VALENZUELA FJ, TORRES-FARFAN C, et al. Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. *Horm Metab Res* 2011; 43:337-342.
99. DICKMEIS T. Glucocorticoids and the circadian clock. *J Endocrinol* 2009; 200:3-22.
100. CHARMANDARI E, CHROUSOS GP, LAMBROU GI, et al. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. *PLoS One* 2011; 6:e25612.
101. KINO T, CHROUSOS GP. Circadian CLOCK-mediated regulation of target-tissue sensitivity to glucocorticoids: implications for cardiometabolic diseases. *Endocr Dev* 2011; 20:116-126.
102. OSTER H, DAMEROW S, KIESSLING S, et al. The circadian rhythm of glucocorticoids is regulated by a gating mechanism residing in the adrenal cortical clock. *Cell Metab* 2006; 4:163-173.
103. PERSENGIEV SP. Multiple domains of melatonin receptor are involved in the regulation of glucocorticoid receptor-induced gene expression. *J Steroid Biochem Mol Biol* 1999; 68:181-187.
104. GAN EH, QUINTON R. Physiological significance of the rhythmic secretion of hypothalamic and pituitary hormones. *Progress in brain research* 2010; 181:111-126.
105. NADER N, CHROUSOS GP, KINO T. Interactions of the circadian CLOCK system and the HPA axis. *Trends Endocrinol Metab* 2010; 21:277-286.
106. QIAN X, DROSTE SK, LIGHTMAN SL, et al. Circadian and ultradian rhythms of free glucocorticoid hormone are highly synchronized between the blood, the subcutaneous tissue, and the brain. *Endocrinology* 2012; 153:4346-4353.
107. CLOW A, HUCKLEBRIDGE F, STALDER T, et al. The cortisol awakening response: more than a measure of HPA axis function. *Neurosci Biobehav Rev* 2010; 35:97-103.
108. WU YH, ZHOU JN, BALESAR R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. *J Comp Neurol* 2006; 499:897-910.

109. MAZZOCCOLI G, CARUGHI S, SPERANDEO M, et al. Neuro-endocrine correlations of hypothalamic-pituitary-thyroid axis in healthy humans. *J Biol Regul Homeost Agents* 2011; 25:249-257.
110. KELLNER M, YASSOURIDIS A, MANZ B, et al. Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers--a potential link to low-melatonin syndrome in depression? *Neuroendocrinology* 1997; 65:284-290.
111. BUCKLEY TM, SCHATZBERG AF. A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker? *J Psychiatr Res* 2010; 44:69-74.
112. HEIM C, NEMEROFF CB. Neurobiology of posttraumatic stress disorder. *CNS spectrums* 2009; 14:13-24.
113. RAISON CL, MILLER AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* 2003; 160:1554-1565.
114. BAUER ME, WIECK A, LOPES RP, et al. Interplay between neuroimmunoendocrine systems during post-traumatic stress disorder: a minireview. *Neuroimmunomodulation* 2010; 17:192-195.
115. PACE TW, HEIM CM. A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. *Brain Behav Immun* 2011; 25:6-13.
116. YEHUDA R. Current status of cortisol findings in post-traumatic stress disorder. *Psychiatr Clin North Am* 2002; 25:341-368, vii.
117. YEHUDA R, GOLIER JA, KAUFMAN S. Circadian rhythm of salivary cortisol in holocaust survivors with and without PTSD. *Am J Psychiatry* 2005; 162:998-U995.
118. BAKER DG, WEST SA, NICHOLSON WE, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. *Am J Psychiatry* 1999; 156:585-588.
119. DE KLOET CS, VERMETTEN E, GEUZE E, et al. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. *J Psychiatr Res* 2006; 40:550-567.
120. VAN LIEMPT S, ARENDS J, CLUITMANS PJ, et al. Sympathetic activity and hypothalamo-pituitary-adrenal axis activity during sleep in post-traumatic stress disorder: a study assessing polysomnography with simultaneous blood sampling. *Psychoneuroendocrinology* 2013; 38:155-165.
121. KEESHIN BR, STRAWN JR, OUT D, et al. Cortisol awakening response in adolescents with acute sexual abuse related posttraumatic stress disorder. *Depress Anxiety* 2014; 31:107-114.

122. YEHUDA R. Status of glucocorticoid alterations in post-traumatic stress disorder. *Ann N Y Acad Sci* 2009; 1179:56-69.
123. NEWPORT DJ, HEIM C, BONSALE R, et al. Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse. *Biol Psychiatry* 2004; 55:10-20.
124. ROHLER N, JOKSIMOVIC L, WOLF JM, et al. Hypocortisolism and increased glucocorticoid sensitivity of pro-inflammatory cytokine production in Bosnian war refugees with posttraumatic stress disorder. *Biol Psychiatry* 2004; 55:745-751.
125. DE KLOET CS, VERMETTEN E, BIKKER A, et al. Leukocyte glucocorticoid receptor expression and immunoregulation in veterans with and without post-traumatic stress disorder. *Mol Psychiatry* 2007; 12:443-453.
126. YEHUDA R, GOLIER JA, YANG RK, et al. Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder. *Biol Psychiatry* 2004; 55:1110-1116.
127. RODENBECK A, HAJAK G. Neuroendocrine dysregulation in primary insomnia. *Rev Neurol (Paris)* 2001; 157:S57-61.
128. VGONTZAS AN, BIXLER EO, LIN HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. *J Clin Endocrinol Metab* 2001; 86:3787-3794.
129. BUCKLEY TM, SCHATZBERG AF. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. *J Clin Endocrinol Metab* 2005; 90:3106-3114.
130. NOVATI A, ROMAN V, CETIN T, et al. Chronically restricted sleep leads to depression-like changes in neurotransmitter receptor sensitivity and neuroendocrine stress reactivity in rats. *Sleep* 2008; 31:1579-1585.
131. BACKHAUS J, JUNGHANNIS K, HOHAGEN F. Sleep disturbances are correlated with decreased morning awakening salivary cortisol. *Psychoneuroendocrinology* 2004; 29:1184-1191.
132. SGOIFO A, BUWALDA B, ROOS M, et al. Effects of sleep deprivation on cardiac autonomic and pituitary-adrenocortical stress reactivity in rats. *Psychoneuroendocrinology* 2006; 31:197-208.
133. BUCKLEY T, DUGGAL V, SCHATZBERG AF. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. *J Clin Sleep Med* 2008; 4:235-241.
134. OTTE C, LENOCI M, METZLER T, et al. Hypothalamic-pituitary-adrenal axis activity and sleep in posttraumatic stress disorder. *Neuropsychopharmacology* 2005; 30:1173-1180.

135. CHROUSOS GP, KINO T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. *Ann N Y Acad Sci* 2009; 1179:153-166.
136. KONAKCHIEVA R, MITEV Y, ALMEIDA OF, et al. Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. *Neuroendocrinology* 1998; 67:171-180.
137. PAWLIKOWSKI M, KOLOMECKA M, WOJTCZAK A, et al. Effects of six months melatonin treatment on sleep quality and serum concentrations of estradiol, cortisol, dehydroepiandrosterone sulfate, and somatomedin C in elderly women. *Neuro Endocrinol Lett* 2002; 23 Suppl 1:17-19.
138. KONAKCHIEVA R, MITEV Y, ALMEIDA OF, et al. Chronic melatonin treatment and the hypothalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release. *Biol Cell* 1997; 89:587-596.
139. SEJIAN V, SRIVASTAVA RS. Effects of Melatonin on Adrenal Cortical Functions of Indian Goats under Thermal Stress. *Vet Med Int* 2010; 2010:348919.
140. VANDEWALLE G, MIDDLETON B, RAJARATNAM SM, et al. Robust circadian rhythm in heart rate and its variability: influence of exogenous melatonin and photoperiod. *J Sleep Res* 2007; 16:148-155.
141. DOMINGUEZ-RODRIGUEZ A, ABREU-GONZALEZ P, SANCHEZ-SANCHEZ JJ, et al. Melatonin and circadian biology in human cardiovascular disease. *J Pineal Res* 2010; 49:14-22.
142. KALSBECK A, YI CX, LA FLEUR SE, et al. Suprachiasmatic nucleus and autonomic nervous system influences on awakening from sleep. *Int Rev Neurobiol* 2010; 93:91-107.
143. RUGER M, SCHEER FA. Effects of circadian disruption on the cardiometabolic system. *Rev Endocr Metab Disord* 2009; 10:245-260.
144. AGORASTOS A, BOEL JA, HEPNER PS, et al. Diminished vagal activity and blunted diurnal variation of heart rate dynamics in posttraumatic stress disorder. *Stress* 2013; 16:300-310.
145. MELLMAN TA, BROWN DD, JENIFER ES, et al. Posttraumatic stress disorder and nocturnal blood pressure dipping in young adult African Americans. *Psychosom Med* 2009; 71:627-630.
146. HALEY RW, VONGPATANASIN W, WOLFE GI, et al. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. *Am J Med* 2004; 117:469-478.

147. YEHUDA R, SIEVER LJ, TEICHER MH, et al. Plasma norepinephrine and 3-methoxy-4-hydroxyphenylglycol concentrations and severity of depression in combat posttraumatic stress disorder and major depressive disorder. *Biol Psychiatry* 1998; 44:56-63.
148. POLE N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. *Psychol Bull* 2007; 133:725-746.
149. WOODWARD SH, ARSENAULT NJ, VOELKER K, et al. Autonomic activation during sleep in posttraumatic stress disorder and panic: a mattress actigraphic study. *Biol Psychiatry* 2009; 66:41-46.
150. THOMA MV, JOKSIMOVIC L, KIRSCHBAUM C, et al. Altered salivary alpha-amylase awakening response in Bosnian War refugees with posttraumatic stress disorder. *Psychoneuroendocrinology* 2012; 37:810-817.
151. O'TOOLE BI, CATTS SV. Trauma, PTSD, and physical health: an epidemiological study of Australian Vietnam veterans. *J Psychosom Res* 2008; 64:33-40.
152. WAGNER AW, WOLFE J, ROTNITSKY A, et al. An investigation of the impact of posttraumatic stress disorder on physical health. *J Trauma Stress* 2000; 13:41-55.
153. BOSCARINO JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. *Psychosom Med* 2008; 70:668-676.
154. KUBZANSKY LD, KOENEN KC, SPIRO A, 3RD, et al. Prospective study of posttraumatic stress disorder symptoms and coronary heart disease in the Normative Aging Study. *Arch Gen Psychiatry* 2007; 64:109-116.
155. COHEN BE, MARMAR CR, NEYLAN TC, et al. Posttraumatic stress disorder and health-related quality of life in patients with coronary heart disease: findings from the Heart and Soul Study. *Arch Gen Psychiatry* 2009; 66:1214-1220.
156. BOSCARINO JA. PTSD is a risk factor for cardiovascular disease: time for increased screening and clinical intervention. *Prev Med* 2012; 54:363-364; author reply 365.
157. REITER RJ, TAN DX, PAREDES SD, et al. Beneficial effects of melatonin in cardiovascular disease. *Ann Med* 2010; 42:276-285.
158. PECHANOVA O, PAULIS L, SIMKO F. Peripheral and central effects of melatonin on blood pressure regulation. *Int J Mol Sci* 2014; 15:17920-17937.
159. SIMKO F, PECHANOVA O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. *J Pineal Res* 2009; 47:127-133.
160. WANG M, YOKOTANI K, NAKAMURA K, et al. Melatonin inhibits the central sympatho-adrenomedullary outflow in rats. *Jpn J Pharmacol* 1999; 81:29-33.

161. MUTOH T, SHIBATA S, KORF HW, et al. Melatonin modulates the light-induced sympathoexcitation and vagal suppression with participation of the suprachiasmatic nucleus in mice. *J Physiol* 2003; 547:317-332.
162. JUSZCZAK K, ZIOMBER A, MACHOWSKA A, et al. The ameliorating effect of exogenous melatonin on urinary bladder function in hyperosmolar bladder overactivity and its influence on the autonomic nervous system activity. *Acta Medica (Hradec Kralove)* 2011; 54:63-68.
163. KITAJIMA T, KANBAYASHI T, SAITOH Y, et al. The effects of oral melatonin on the autonomic function in healthy subjects. *Psychiatry Clin Neurosci* 2001; 55:299-300.
164. NISHIYAMA K, YASUE H, MORIYAMA Y, et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. *Am Heart J* 2001; 141:E9.
165. BRUSCO LI, GARCIA-BONACHO M, ESQUIFINO AI, et al. Diurnal rhythms in norepinephrine and acetylcholine synthesis of sympathetic ganglia, heart and adrenals of aging rats: effect of melatonin. *J Auton Nerv Syst* 1998; 74:49-61.
166. BUDHRAM R, LAU-CAM CA. Attenuating effect of melatonin on pyridoxal-stimulated release of adrenomedullary catecholamines in the rat. *Life Sci* 2009; 84:696-704.
167. SCHACHINGER H, BLUMENTHAL TD, RICHTER S, et al. Melatonin reduces arousal and startle responsiveness without influencing startle habituation or affective startle modulation in young women. *Horm Behav* 2008; 54:258-262.
168. MULLER MD, SAUDER CL, RAY CA. Melatonin attenuates the skin sympathetic nerve response to mental stress. *Am J Physiol Heart Circ Physiol* 2013; 305:H1382-1386.
169. RAY CA. Melatonin attenuates the sympathetic nerve responses to orthostatic stress in humans. *J Physiol* 2003; 551:1043-1048.
170. LORTON D, LUBAHN CL, ESTUS C, et al. Bidirectional communication between the brain and the immune system: implications for physiological sleep and disorders with disrupted sleep. *Neuroimmunomodulation* 2006; 13:357-374.
171. BRYANT PA, TRINDER J, CURTIS N. Sick and tired: Does sleep have a vital role in the immune system? *Nat Rev Immunol* 2004; 4:457-467.
172. COOGAN AN, WYSE CA. Neuroimmunology of the circadian clock. *Brain Res* 2008; 1232:104-112.
173. IMERI L, OPP MR. How (and why) the immune system makes us sleep. *Nat Rev Neurosci* 2009; 10:199-210.
174. IRWIN M. Effects of sleep and sleep loss on immunity and cytokines. *Brain Behav Immun* 2002; 16:503-512.

175. CURTIS AM, BELLET MM, SASSONE-CORSI P, et al. Circadian Clock Proteins and Immunity. *Immunity* 2014; 40:178-186.
176. CERMAKIAN N, LANGE T, GOLOMBEK D, et al. Crosstalk between the circadian clock circuitry and the immune system. *Chronobiol Int* 2013; 30:870-888.
177. PIERPAOLI W. Neuroimmunomodulation of aging. A program in the pineal gland. *Ann N Y Acad Sci* 1998; 840:491-497.
178. SKWARLO-SONTA K, MAJEWSKI P, MARKOWSKA M, et al. Bidirectional communication between the pineal gland and the immune system. *Can J Physiol Pharmacol* 2003; 81:342-349.
179. SCHEIERMANN C, KUNISAKI Y, FRENETTE PS. Circadian control of the immune system. *Nat Rev Immunol* 2013; 13:190-198.
180. VGONTZAS AN, CHROUSOS GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. *Endocrinol Metab Clin North Am* 2002; 31:15-36.
181. BAUER ME, JECKEL CM, LUZ C. The role of stress factors during aging of the immune system. *Ann N Y Acad Sci* 2009; 1153:139-152.
182. GLASER R, KIECOLT-GLASER JK. Stress-induced immune dysfunction: implications for health. *Nat Rev Immunol* 2005; 5:243-251.
183. WEBSTER MARKETON JI, GLASER R. Stress hormones and immune function. *Cell Immunol* 2008; 252:16-26.
184. ROHLEDER N, KARL A. Role of endocrine and inflammatory alterations in comorbid somatic diseases of post-traumatic stress disorder. *Minerva Endocrinol* 2006; 31:273-288.
185. SMITH AK, CONNEELY KN, KILARU V, et al. Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. *Am J Med Genet B Neuropsychiatr Genet* 2011; 156B:700-708.
186. SPIVAK B, SHOHAT B, MESTER R, et al. Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. *Biol Psychiatry* 1997; 42:345-348.
187. MAES M, LIN AH, DELMEIRE L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. *Biol Psychiatry* 1999; 45:833-839.
188. SUTHERLAND AG, ALEXANDER DA, HUTCHISON JD. Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. *Cytokine* 2003; 24:219-225.
189. SPITZER C, BARNOW S, VOLZKE H, et al. Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: evidence from the general population. *J Psychiatr Res* 2010; 44:15-21.



190. KAWAMURA N, KIM Y, ASUKAI N. Suppression of cellular immunity in men with a past history of posttraumatic stress disorder. *Am J Psychiatry* 2001; 158:484-486.
191. VON KANEL R, HEPP U, KRAEMER B, et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. *J Psychiatr Res* 2007; 41:744-752.
192. HOGE EA, BRANDSTETTER K, MOSHIER S, et al. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. *Depress Anxiety* 2009; 26:447-455.
193. BAKER DG, EKHATOR NN, KASCKOW JW, et al. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. *Neuroimmunomodulation* 2001; 9:209-217.
194. GLAESMER H, BRAHLER E, GUNDEL H, et al. The association of traumatic experiences and posttraumatic stress disorder with physical morbidity in old age: a German population-based study. *Psychosom Med* 2011; 73:401-406.
195. BOSCARINO JA. Posttraumatic stress disorder and mortality among U.S. Army veterans 30 years after military service. *Ann Epidemiol* 2006; 16:248-256.
196. ERALY SA, NIEVERGELT CM, MAIHOFER AX, et al. Assessment of Plasma C-Reactive Protein as a Biomarker of Posttraumatic Stress Disorder Risk. *JAMA Psychiatry* 2014.
197. SKWARLO-SONTA K. Melatonin in immunity: comparative aspects. *Neuro Endocrinol Lett* 2002; 23 Suppl 1:61-66.
198. MAVROUDIS PD, SCHEFF JD, CALVANO SE, et al. Systems biology of circadian-immune interactions. *J Innate Immun* 2013; 5:153-162.
199. CALVO JR, GONZALEZ-YANES C, MALDONADO MD. The role of melatonin in the cells of the innate immunity: a review. *J Pineal Res* 2013; 55:103-120.
200. CARRILLO-VICO A, GUERRERO JM, LARDONE PJ, et al. A review of the multiple actions of melatonin on the immune system. *Endocrine* 2005; 27:189-200.
201. CARRILLO-VICO A, REITER RJ, LARDONE PJ, et al. The modulatory role of melatonin on immune responsiveness. *Curr Opin Investig Drugs* 2006; 7:423-431.
202. MARKUS RP, FERREIRA ZS, FERNANDES PA, et al. The immune-pineal axis: a shuttle between endocrine and paracrine melatonin sources. *Neuroimmunomodulation* 2007; 14:126-133.
203. CARRILLO-VICO A, LARDONE PJ, ALVAREZ-SANCHEZ N, et al. Melatonin: buffering the immune system. *Int J Mol Sci* 2013; 14:8638-8683.
204. GIANNOULIA-KARANTANA A, VLACHOU A, POLYCHRONOPOULOU S, et al. Melatonin and immunomodulation: connections and potential clinical applications. *Neuroimmunomodulation* 2006; 13:133-144.

205. OCHOA JJ, DIAZ-CASTRO J, KAJARABILLE N, et al. Melatonin supplementation ameliorates oxidative stress and inflammatory signaling induced by strenuous exercise in adult human males. *J Pineal Res* 2011; 51:373-380.
206. SRINIVASAN V, SPENCE DW, TRAKHT I, et al. Immunomodulation by melatonin: its significance for seasonally occurring diseases. *Neuroimmunomodulation* 2008; 15:93-101.
207. MAESTRONI GJ, CONTI A. The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. *J Neuroimmunol* 1990; 28:167-176.
208. MAESTRONI GJ. MLT and the immune-hematopoietic system. *Adv Exp Med Biol* 1999; 460:395-405.
209. HOTCHKISS AK, NELSON RJ. Melatonin and immune function: hype or hypothesis? *Crit Rev Immunol* 2002; 22:351-371.
210. CUZZOCREA S, REITER RJ. Pharmacological actions of melatonin in acute and chronic inflammation. *Curr Top Med Chem* 2002; 2:153-165.
211. RADOGNA F, DIEDERICH M, GHIBELLI L. Melatonin: a pleiotropic molecule regulating inflammation. *Biochem Pharmacol* 2010; 80:1844-1852.
212. CARDINALI DP, ESQUIFINO AI, SRINIVASAN V, et al. Melatonin and the immune system in aging. *Neuroimmunomodulation* 2008; 15:272-278.
213. MAESTRONI GJ. The immunoneuroendocrine role of melatonin. *J Pineal Res* 1993; 14:1-10.
214. SACCO S, AQUILINI L, GHEZZI P, et al. Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro. *Eur J Pharmacol* 1998; 343:249-255.
215. VISHWAS DK, MUKHERJEE A, HALDAR C. Melatonin improves humoral and cell-mediated immune responses of male golden hamster following stress induced by dexamethasone. *J Neuroimmunol* 2013; 259:17-25.
216. CANO BARQUILLA P, PAGANO ES, JIMENEZ-ORTEGA V, et al. Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. *J Pineal Res* 2014; 57:280-290.
217. AGIL A, REITER RJ, JIMENEZ-ARANDA A, et al. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. *J Pineal Res* 2013; 54:381-388.
218. SANCAR G, BRUNNER M. Circadian clocks and energy metabolism. *Cell Mol Life Sci* 2014; 71(14):2667-2680.
219. GARAULET M, MADRID JA. Chronobiological aspects of nutrition, metabolic syndrome and obesity. *Adv Drug Deliv Rev* 2010; 62:967-978.

220. REITER RJ, TAN DX, KORKMAZ A, et al. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. *Ann Med* 2012; 44:564-577.
221. BOYKO EJ, SEELIG AD, JACOBSON IG, et al. Sleep characteristics, mental health, and diabetes risk: a prospective study of U.S. military service members in the Millennium Cohort Study. *Diabetes Care* 2013; 36:3154-3161.
222. BARTOLI F, CARRA G, CROCAMO C, et al. Metabolic syndrome in people suffering from posttraumatic stress disorder: a systematic review and meta-analysis. *Metab Syndr Relat Disord* 2013; 11:301-308.
223. HEPPNER PS, CRAWFORD EF, HAJI UA, et al. The association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in veterans. *BMC Med* 2009; 7:1.
224. PAGOTO SL, SCHNEIDER KL, BODENLOS JS, et al. Association of post-traumatic stress disorder and obesity in a nationally representative sample. *Obesity (Silver Spring)* 2012; 20:200-205.
225. LEVINE AB, LEVINE LM, LEVINE TB. Posttraumatic stress disorder and cardiometabolic disease. *Cardiology* 2014; 127:1-19.
226. KUBZANSKY LD, BORDELOIS P, JUN HJ, et al. The weight of traumatic stress: a prospective study of posttraumatic stress disorder symptoms and weight status in women. *JAMA Psychiatry* 2014; 71:44-51.
227. VACCARINO V, GOLDBERG J, MAGRUDER KM, et al. Posttraumatic stress disorder and incidence of type-2 diabetes: a prospective twin study. *J Psychiatr Res* 2014; 56:158-164.
228. MAIA DB, MARMAR CR, MENDLOWICZ MV, et al. Abnormal serum lipid profile in Brazilian police officers with post-traumatic stress disorder. *J Affect Disord* 2008; 107:259-263.
229. NAVARRO-ALARCON M, RUIZ-OJEDA FJ, BLANCA-HERRERA RM, et al. Melatonin and metabolic regulation: a review. *Food Funct* 2014; 5:2806-2832.
230. CIPOLLA-NETO J, AMARAL FG, AFECHÉ SC, et al. Melatonin, energy metabolism, and obesity: a review. *J Pineal Res* 2014; 56:371-381.
231. CARDINALI DP, CANO P, JIMENEZ-ORTEGA V, et al. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. *Neuroendocrinology* 2011; 93:133-142.
232. ROBEVA R, KIRILOV G, TOMOVA A, et al. Melatonin-insulin interactions in patients with metabolic syndrome. *J Pineal Res* 2008; 44:52-56.
233. HUSSEIN MR, AHMED OG, HASSAN AF, et al. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological

- pathologies associated with obesity: an animal model. *Int J Exp Pathol* 2007; 88:19-29.
234. BONNEFONT-ROUSSELOT D. Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. *Endocr Metab Immune Disord Drug Targets* 2014; 14:159-168.
235. KOZIROG M, POLIWCAZAK AR, DUCHNOWICZ P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. *J Pineal Res* 2011; 50:261-266.
236. TAMURA H, NAKAMURA Y, NARIMATSU A, et al. Melatonin treatment in peri- and postmenopausal women elevates serum high-density lipoprotein cholesterol levels without influencing total cholesterol levels. *J Pineal Res* 2008; 45:101-105.
237. GARFINKEL D, ZORIN M, WAINSTEIN J, et al. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. *Diabetes Metab Syndr Obes* 2011; 4:307-313.
238. MODABBERNIA A, HEIDARI P, SOLEIMANI R, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. *J Psychiatr Res* 2014; 53:133-140.
239. KORKMAZ A, ROSALES-CORRAL S, REITER RJ. Gene regulation by melatonin linked to epigenetic phenomena. *Gene* 2012; 503:1-11.
240. SCHIAVONE S, COLAIANNA M, CURTIS L. Impact of early life stress on the pathogenesis of mental disorders: relation to brain oxidative stress. *Curr Pharm Des* 2015; 21:1404-1412.
241. PRICE LH, KAO HT, BURGERS DE, et al. Telomeres and early-life stress: an overview. *Biol Psychiatry* 2013; 73:15-23.
242. HARDELAND R. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. *J Pineal Res* 2013; 55:325-356.
243. JERGOVIC M, TOMICEVIC M, VIDOVIC A, et al. Telomere shortening and immune activity in war veterans with posttraumatic stress disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2014; 54:275-283.
244. O'DONOVAN A, EPEL E, LIN J, et al. Childhood trauma associated with short leukocyte telomere length in posttraumatic stress disorder. *Biol Psychiatry* 2011; 70:465-471.
245. ZHANG L, HU XZ, BENEDEK DM, et al. The interaction between stressful life events and leukocyte telomere length is associated with PTSD. *Mol Psychiatry* 2014; 19:855-856.

246. MICHELS L, SCHULTE-VELS T, SCHICK M, et al. Prefrontal GABA and glutathione imbalance in posttraumatic stress disorder: preliminary findings. *Psychiatry Res* 2014; 224:288-295.
247. GAUTAM A, D'ARPA P, DONOHUE DE, et al. Acute and chronic plasma metabolomic and liver transcriptomic stress effects in a mouse model with features of post-traumatic stress disorder. *PLoS One* 2015; 10:e0117092.
248. WILSON CB, MCLAUGHLIN LD, NAIR A, et al. Inflammation and oxidative stress are elevated in the brain, blood, and adrenal glands during the progression of post-traumatic stress disorder in a predator exposure animal model. *PLoS One* 2013; 8:e76146.
249. MILLER MW, SADEH N. Traumatic stress, oxidative stress and post-traumatic stress disorder: neurodegeneration and the accelerated-aging hypothesis. *Mol Psychiatry* 2014.
250. TAN DX, MANCHESTER LC, ESTEBAN-ZUBERO E, et al. Melatonin as a Potent and Inducible Endogenous Antioxidant: Synthesis and Metabolism. *Molecules* 2015; 20:18886-18906.
251. GALANO A, TAN DX, REITER RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. *J Pineal Res* 2011; 51:1-16.
252. REITER RJ, CALVO JR, KARBOWNIK M, et al. Melatonin and its relation to the immune system and inflammation. *Ann N Y Acad Sci* 2000; 917:376-386.
253. HARDELAND R, CARDINALI DP, BROWN GM, et al. Melatonin and brain inflammaging. *Prog Neurobiol* 2015.
254. SANCHEZ A, CALPENA AC, CLARES B. Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. *Int J Mol Sci* 2015; 16:16981-17004.
255. ZHANG HM, ZHANG Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. *J Pineal Res* 2014; 57:131-146.
256. GALANO A, MEDINA ME, TAN DX, et al. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. *J Pineal Res* 2015; 58:107-116.
257. RAMIS MR, ESTEBAN S, MIRALLES A, et al. Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review. *Curr Med Chem* 2015; 22:2690-2711.
258. ROMERO A, RAMOS E, DE LOS RIOS C, et al. A review of metal-catalyzed molecular damage: protection by melatonin. *J Pineal Res* 2014; 56:343-370.
259. YADAV SK, HALDAR C. Experimentally induced stress, oxidative load and changes in immunity in a tropical wild bird, *Perdica asiatica*: involvement of melatonin and glucocorticoid receptors. *Zoology* 2014; 117:261-268.

260. QUIROS I, MAYO JC, GARCIA-SUAREZ O, et al. Melatonin prevents glucocorticoid inhibition of cell proliferation and toxicity in hippocampal cells by reducing glucocorticoid receptor nuclear translocation. *J Steroid Biochem Mol Biol* 2008; 110:116-124.
261. SAINZ RM, MAYO JC, REITER RJ, et al. Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus. *FASEB J* 1999; 13:1547-1556.
262. ALI T, BADSHAH H, KIM TH, et al. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model. *J Pineal Res* 2015; 58:71-85.
263. RODRIGUEZ-RODRIGUEZ A, EGEA-GUERRERO JJ, MURILLO-CABEZAS F, et al. Oxidative stress in traumatic brain injury. *Curr Med Chem* 2014; 21:1201-1211.
264. CORNELIUS C, CRUPI R, CALABRESE V, et al. Traumatic brain injury: oxidative stress and neuroprotection. *Antioxid Redox Signal* 2013; 19:836-853.
265. LOZANO D, GONZALES-PORTILLO GS, ACOSTA S, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. *Neuropsychiatr Dis Treat* 2015; 11:97-106.
266. BAHRAINI NH, BRESHEARS RE, HERNANDEZ TD, et al. Traumatic brain injury and posttraumatic stress disorder. *Psychiatr Clin North Am* 2014; 37:55-75.
267. RAGSDALE KA, NEER SM, BEIDEL DC, et al. Posttraumatic stress disorder in OEF/OIF veterans with and without traumatic brain injury. *J Anxiety Dis* 2013; 27:420-426.
268. TANEV KS, PENTEL KZ, KREDLOW MA, et al. PTSD and TBI co-morbidity: scope, clinical presentation and treatment options. *Brain Inj* 2014; 28:261-270.
269. CARLSON KF, KEHLE SM, MEIS LA, et al. Prevalence, assessment, and treatment of mild traumatic brain injury and posttraumatic stress disorder: a systematic review of the evidence. *J Head Trauma Rehab* 2011; 26:103-115.
270. COSTANZO ME, CHOU YY, LEAMAN S, et al. Connecting combat-related mild traumatic brain injury with posttraumatic stress disorder symptoms through brain imaging. *Neurosci Lett* 2014; 577:11-15.
271. HOGE CW, MCGURK D, THOMAS JL, et al. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. *N Engl J Med* 2008; 358:453-463.
272. SCHNEIDERMAN AI, BRAVER ER, KANG HK. Understanding sequelae of injury mechanisms and mild traumatic brain injury incurred during the conflicts in Iraq and Afghanistan: persistent postconcussive symptoms and posttraumatic stress disorder. *Am J Epidemiol* 2008; 167:1446-1452.

273. PRASAD KN, BONDY SC. Common biochemical defects linkage between post-traumatic stress disorders, mild traumatic brain injury (TBI) and penetrating TBI. *Brain Res* 2015; 1599C:103-114.
274. SPIELBERG JM, MCGLINCHEY RE, MILBERG WP, et al. Brain Network Disturbance Related to Posttraumatic Stress and Traumatic Brain Injury in Veterans. *Biol Psychiatry* 2015.
275. WILLIAMSON JB, HEILMAN KM, PORGES EC, et al. A possible mechanism for PTSD symptoms in patients with traumatic brain injury: central autonomic network disruption. *Front Neuroeng* 2013; 6:13.
276. YURGIL KA, BARKAUSKAS DA, VASTERLING JJ, et al. Association between traumatic brain injury and risk of posttraumatic stress disorder in active-duty Marines. *JAMA Psychiatry* 2014; 71:149-157.
277. NASEEM M, PARVEZ S. Role of melatonin in traumatic brain injury and spinal cord injury. *ScientificWorldJournal* 2014; 2014:586270.
278. OZDEMIR D, UYSAL N, GONENC S, et al. Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats. *Physiol Res* 2005; 54:631-637.
279. KEMP S, BISWAS R, NEUMANN V, et al. The value of melatonin for sleep disorders occurring post-head injury: a pilot RCT. *Brain injury* 2004; 18:911-919.
280. DING K, WANG H, XU J, et al. Melatonin stimulates antioxidant enzymes and reduces oxidative stress in experimental traumatic brain injury: the Nrf2-ARE signaling pathway as a potential mechanism. *Free Radic Biol Med* 2014; 73:1-11.
281. SAMANTARAY S, DAS A, THAKORE NP, et al. Therapeutic potential of melatonin in traumatic central nervous system injury. *J Pineal Res* 2009; 47:134-142.
282. OZDEMIR D, TUGYAN K, UYSAL N, et al. Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. *Neurosci Lett* 2005; 385:234-239.
283. HAGHIGHI F, GE Y, CHEN S, et al. Neuronal DNA Methylation Profiling of Blast-Related Traumatic Brain Injury. *J Neurotrauma* 2015.
284. GERSTNER JR, LYONS LC, WRIGHT KP, JR., et al. Cycling behavior and memory formation. *J Neurosci* 2009; 29:12824-12830.
285. GERSTNER JR, YIN JC. Circadian rhythms and memory formation. *Nat Rev Neurosci* 2010; 11:577-588.
286. RUBY NF, FERNANDEZ F, GARRETT A, et al. Spatial memory and long-term object recognition are impaired by circadian arrhythmia and restored by the GABA<sub>A</sub> antagonist pentylene-tetrazole. *PLoS One* 2013; 8:e72433.

287. HINKELMANN K, MUHTZ C, DETTENBORN L, et al. Association between cortisol awakening response and memory function in major depression. *Psychol Med* 2013;1-9.
288. ALBRECHT U. The circadian clock, reward, and memory. *Front Mol Neurosci* 2011; 4:41.
289. DIEKELMANN S, WILHELM I, BORN J. The whats and whens of sleep-dependent memory consolidation. *Sleep Med Rev* 2009; 13:309-321.
290. GORFINE T, ZISAPEL N. Melatonin and the human hippocampus, a time dependent interplay. *J Pineal Res* 2007; 43:80-86.
291. LYONS LC, GREEN CL, ESKIN A. Intermediate-term memory is modulated by the circadian clock. *J Biol Rhythms* 2008; 23:538-542.
292. RUBY NF, HWANG CE, WESSELLS C, et al. Hippocampal-dependent learning requires a functional circadian system. *Proc Natl Acad Sci U S A* 2008; 105:15593-15598.
293. WAGNER U, BORN J. Memory consolidation during sleep: interactive effects of sleep stages and HPA regulation. *Stress* 2008; 11:28-41.
294. RAWASHDEH O, MARONDE E. The hormonal Zeitgeber melatonin: role as a circadian modulator in memory processing. *Front Mol Neurosci* 2012; 5:27.
295. YOO SS, GUJAR N, HU P, et al. The human emotional brain without sleep--a prefrontal amygdala disconnect. *Curr Biol* 2007; 17:R877-878.
296. HAGEWOUD R, WHITCOMB SN, HEERINGA AN, et al. A time for learning and a time for sleep: the effect of sleep deprivation on contextual fear conditioning at different times of the day. *Sleep* 2010; 33:1315-1322.
297. GRAVES LA, HELLER EA, PACK AI, et al. Sleep deprivation selectively impairs memory consolidation for contextual fear conditioning. *Learn Mem* 2003; 10:168-176.
298. ZELINSKI EL, TYNDALL AV, HONG NS, et al. Persistent impairments in hippocampal, dorsal striatal, and prefrontal cortical function following repeated photoperiod shifts in rats. *Exp Brain Res* 2013; 224:125-139.
299. MENZ MM, RIHM JS, SALARI N, et al. The role of sleep and sleep deprivation in consolidating fear memories. *Neuroimage* 2013; 75:87-96.
300. ALKADHI K, ZAGAAR M, ALHAIDER I, et al. Neurobiological consequences of sleep deprivation. *Curr Neuropharmacol* 2013; 11:231-249.
301. MCCOY JG, STRECKER RE. The cognitive cost of sleep lost. *Neurobiol Learn Mem* 2011; 96:564-582.
302. GRITTON HJ, KANTOROWSKI A, SARTER M, et al. Bidirectional interactions between circadian entrainment and cognitive performance. *Learn Mem* 2012; 19:126-141.



303. REID KJ, MCGEE-KOCH LL, ZEE PC. Cognition in circadian rhythm sleep disorders. *Prog Brain Res* 2011; 190:3-20.
304. MCKENNA BS, EYLER LT. Overlapping prefrontal systems involved in cognitive and emotional processing in euthymic bipolar disorder and following sleep deprivation: a review of functional neuroimaging studies. *Clin Psychol Rev* 2012; 32:650-663.
305. GUMENYUK V, HOWARD R, ROTH T, et al. Sleep loss, circadian mismatch, and abnormalities in reorienting of attention in night workers with shift work disorder. *Sleep* 2014; 37:545-556.
306. HENCKENS MJ, HERMANS EJ, PU Z, et al. Stressed memories: how acute stress affects memory formation in humans. *J Neurosci* 2009; 29:10111-10119.
307. WOON FL, SOOD S, HEDGES DW. Hippocampal volume deficits associated with exposure to psychological trauma and posttraumatic stress disorder in adults: a meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34:1181-1188.
308. BOB P, FEDOR-FREYBERGH P. Melatonin, consciousness, and traumatic stress. *J Pineal res* 2008; 44:341-347.
309. MOORE SA. Cognitive abnormalities in posttraumatic stress disorder. *Curr Opin Psychiatry* 2009; 22:19-24.
310. MCNALLY RJ. Cognitive abnormalities in post-traumatic stress disorder. *Trends Cogn Sci* 2006; 10:271-277.
311. BREWIN CR. The nature and significance of memory disturbance in posttraumatic stress disorder. *Annu Rev Clin Psychol* 2011; 7:203-227.
312. TEMPESTA D, MAZZA M, IARIA G, et al. A specific deficit in spatial memory acquisition in post-traumatic stress disorder and the role of sleep in its consolidation. *Hippocampus* 2011.
313. WILKER S, ELBERT T, KOLASSA IT. The downside of strong emotional memories: how human memory-related genes influence the risk for posttraumatic stress disorder--a selective review. *Neurobiol Learn Mem* 2014; 112:75-86.
314. GOLIER JA, HARVEY PD, LEGGE J, et al. Memory performance in older trauma survivors: implications for the longitudinal course of PTSD. *Ann N Y Acad Sci* 2006; 1071:54-66.
315. WOLFE J, SCHLESINGER LK. Performance of PTSD patients on standard tests of memory. Implications for trauma. *Ann N Y Acad Sci* 1997; 821:208-218.
316. POLAK AR, WITTEVEEN AB, REITSMA JB, et al. The role of executive function in posttraumatic stress disorder: a systematic review. *J Affect Disord* 2012; 141:11-21.
317. HUGHES KC, SHIN LM. Functional neuroimaging studies of post-traumatic stress disorder. *Expert Rev Neurother* 2011; 11:275-285.

318. BREMNER JD. The relationship between cognitive and brain changes in posttraumatic stress disorder. *Ann N Y Acad Sci* 2006; 1071:80-86.
319. TSOORY MM, VOUMBA RM, AKIRAV I, et al. Amygdala modulation of memory-related processes in the hippocampus: potential relevance to PTSD. *Prog Brain Res* 2008; 167:35-51.
320. GOOSENS KA. Hippocampal regulation of aversive memories. *Curr Opin Neurobiol* 2011; 21:460-466.
321. ACHESON DT, GRESACK JE, RISBROUGH VB. Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. *Neuropharmacology* 2012; 62:674-685.
322. KOENIGS M, GRAFMAN J. Posttraumatic stress disorder: the role of medial prefrontal cortex and amygdala. *Neuroscientist* 2009; 15:540-548.
323. LAYTON B, KRİKORIAN R. Memory mechanisms in posttraumatic stress disorder. *J Neuropsychiatr Clin Neurosci* 2002; 14:254-261.
324. IKENO T, WEIL ZM, NELSON RJ. Photoperiod affects the diurnal rhythm of hippocampal neuronal morphology of siberian hamsters. *Chronobiol Int* 2013; 30:1089-1100.
325. MUSIEK ES, LIM MM, YANG G, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. *J Clin Invest* 2013; 123:5389-5400.
326. BOUCHARD-CANNON P, MENDOZA-VIVEROS L, YUEN A, et al. The circadian molecular clock regulates adult hippocampal neurogenesis by controlling the timing of cell-cycle entry and exit. *Cell Rep* 2013; 5:961-973.
327. BALTAZAR RM, COOLEN LM, WEBB IC. Diurnal rhythms in neural activation in the mesolimbic reward system: critical role of the medial prefrontal cortex. *Eur J Neurosci* 2013; 38:2319-2327.
328. VECSEY CG, PEIXOTO L, CHOI JH, et al. Genomic analysis of sleep deprivation reveals translational regulation in the hippocampus. *Physiol Genomics* 2012; 44:981-991.
329. RAWASHDEH O, JILG A, JEDLICKA P, et al. PERIOD1 coordinates hippocampal rhythms and memory processing with daytime. *Hippocampus* 2014.
330. RIMMELE U, SPILLMANN M, BARTSCHI C, et al. Melatonin improves memory acquisition under stress independent of stress hormone release. *Psychopharmacology (Berl)* 2009; 202:663-672.
331. CONBOY L, TANRIKUT C, ZOLADZ PR, et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. *Int J Neuropsychopharmacol* 2009; 12:329-341.

332. GORFINE T, YESHURUN Y, ZISAPEL N. Nap and melatonin-induced changes in hippocampal activation and their role in verbal memory consolidation. *J Pineal Res* 2007; 43:336-342.
333. BAYDAS G, NEDZVETSKY VS, NERUSH PA, et al. A novel role for melatonin: regulation of the expression of cell adhesion molecules in the rat hippocampus and cortex. *Neurosci Lett* 2002; 326:109-112.
334. ZHANG L, ZHANG HQ, LIANG XY, et al. Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: role of oxidative stress, BDNF and CaMKII. *Behav Brain Res* 2013; 256:72-81.
335. TONGJAROENBUANGAM W, RUKSEE N, MAHANAM T, et al. Melatonin attenuates dexamethasone-induced spatial memory impairment and dexamethasone-induced reduction of synaptic protein expressions in the mouse brain. *Neurochem Int* 2013; 63:482-491.
336. EKTHUWAPRANEE K, SOTTHIBUNDHU A, TOCHARUS C, et al. Melatonin ameliorates dexamethasone-induced inhibitory effects on the proliferation of cultured progenitor cells obtained from adult rat hippocampus. *J Steroid Biochem Mol Biol* 2015; 145:38-48.
337. PECK JS, LEGOFF DB, AHMED I, et al. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. *Am J Geriatr Psychiatry* 2004; 12:432-436.
338. GUMUSLU E, MUTLU O, SUNNETCI D, et al. The Antidepressant Agomelatine Improves Memory Deterioration and Upregulates CREB and BDNF Gene Expression Levels in Unpredictable Chronic Mild Stress (UCMS)-Exposed Mice. *Drug target insights* 2014; 8:11-21.
339. HARIDAS S, KUMAR M, MANDA K. Melatonin ameliorates chronic mild stress induced behavioral dysfunctions in mice. *Physiol Behav* 2013; 119:201-207.
340. KWON KJ, LEE EJ, KIM MK, et al. The potential role of melatonin on sleep deprivation-induced cognitive impairments: Implication of FMRP on cognitive function. *Neuroscience* 2015; 301:403-414.
341. HUANG F, YANG Z, LIU X, et al. Melatonin facilitates extinction, but not acquisition or expression, of conditional cued fear in rats. *BMC Neuroscience* 2014; 15:86.
342. OTMANI S, DEMAZIERES A, STANER C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. *Hum Psychopharmacol* 2008; 23:693-705.
343. CAIN CK, MAYNARD GD, KEHNE JH. Targeting memory processes with drugs to prevent or cure PTSD. *Expert Opin Investig Drugs* 2012; 21:1323-1350.

344. MCWILLIAMS LA, COX BJ, ENNS MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. *Pain* 2003; 106:127-133.
345. ARGUELLES LM, AFARI N, BUCHWALD DS, et al. A twin study of posttraumatic stress disorder symptoms and chronic widespread pain. *Pain* 2006; 124:150-157.
346. MOELLER-BERTRAM T, KELTNER J, STRIGO IA. Pain and post traumatic stress disorder - review of clinical and experimental evidence. *Neuropharmacology* 2012; 62:586-597.
347. RAPHAEL KG, JANAL MN, NAYAK S. Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women. *Pain Med* 2004; 5:33-41.
348. TURNER-COBB JM, OSBORN M, DA SILVA L, et al. Sex differences in hypothalamic-pituitary-adrenal axis function in patients with chronic pain syndrome. *Stress* 2010; 13:292-300.
349. WINGENFELD K, HEIM C, SCHMIDT I, et al. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. *Psychosom Med* 2008; 70:65-72.
350. BLACKBURN-MUNRO G. Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression. *Curr Pain Headache Rep* 2004; 8:116-124.
351. MCEWEN BS, KALIA M. The role of corticosteroids and stress in chronic pain conditions. *Metabolism* 2010; 59 Suppl 1:S9-15.
352. BLACKBURN-MUNRO G, BLACKBURN-MUNRO R. Pain in the brain: are hormones to blame? *Trends Endocrinol Metab* 2003; 14:20-27.
353. PETRELLUZZI KF, GARCIA MC, PETTA CA, et al. Salivary cortisol concentrations, stress and quality of life in women with endometriosis and chronic pelvic pain. *Stress* 2008; 11:390-397.
354. RIVA R, MORK PJ, WESTGAARD RH, et al. Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. *Psychoneuroendocrinology* 2012; 37:299-306.
355. GILRON I, BAILEY JM, VANDENKERKHOF EG. Chronobiological characteristics of neuropathic pain: clinical predictors of diurnal pain rhythmicity. *Clin J Pain* 2013; 29:755-759.
356. BACHMANN CG, NITSCHKE MA, PFINGSTEN M, et al. Diurnal time course of heat pain perception in healthy humans. *Neurosci Lett* 2011; 489:122-125.

357. ODRICICH M, BAILEY JM, CAHILL CM, et al. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. *Pain* 2006; 120:207-212.
358. ROEHRS T, ROTH T. Sleep and pain: interaction of two vital functions. *Semin Neurol* 2005; 25:106-116.
359. LAUTENBACHER S, KUNDERMANN B, KRIEG JC. Sleep deprivation and pain perception. *Sleep Med Rev* 2006; 10:357-369.
360. ALSAADI SM, MCAULEY JH, HUSH JM, et al. The Bidirectional Relationship Between Pain Intensity and Sleep Disturbance/Quality in Patients with Low Back Pain. *Clin J Pain* 2014.
361. KUNDERMANN B, KRIEG JC, SCHREIBER W, et al. The effect of sleep deprivation on pain. *Pain Res Manag* 2004; 9:25-32.
362. AZEVEDO E, MANZANO GM, SILVA A, et al. The effects of total and REM sleep deprivation on laser-evoked potential threshold and pain perception. *Pain* 2011; 152:2052-2058.
363. OKIFUJI A, HARE BD. Do sleep disorders contribute to pain sensitivity? *Curr Rheumatol Rep* 2011; 13:528-534.
364. SADEK K, MACKLON N, BRUCE K, et al. Hypothesis: Role for the circadian Clock system and sleep in the pathogenesis of adhesions and chronic pelvic pain? *Med Hypotheses* 2011; 76:453-456.
365. JUNKER U, WIRZ S. Review article: chronobiology: influence of circadian rhythms on the therapy of severe pain. *J Oncol Pharm Pract* 2010; 16:81-87.
366. SRINIVASAN V, ZAKARIA R, JEET SINGH H, et al. Melatonin and its agonists in pain modulation and its clinical application. *Arch Ital Biol* 2012; 150:274-289.
367. AMBRIZ-TUTUTI M, ROCHA-GONZALEZ HI, CRUZ SL, et al. Melatonin: a hormone that modulates pain. *Life Sci* 2009; 84:489-498.
368. SRINIVASAN V, PANDI-PERUMAL SR, SPENCE DW, et al. Potential use of melatonergic drugs in analgesia: Mechanisms of action. *Brain Res Bull* 2010; 81:362-371.
369. WILHELMSSEN M, AMIRIAN I, REITER RJ, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. *J Pineal Res* 2011; 51:270-277.
370. ESPOSITO E, PATERNITI I, MAZZON E, et al. Melatonin reduces hyperalgesia associated with inflammation. *J Pineal Res* 2010; 49:321-331.
371. JUSZCZAK M, STEMPNIAK B. Melatonin inhibits the substance P-induced secretion of vasopressin and oxytocin from the rat hypothalamo-neurohypophysial system: in vitro studies. *Brain Res Bull* 2003; 59:393-397.

372. NELSON FA, FARR LA, EBADI M. Salivary melatonin response to acute pain stimuli. *J Pineal Res* 2001; 30:206-212.
373. BORAZAN H, TUNCER S, YALCIN N, et al. Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial. *J Anesth* 2010; 24:155-160.
374. STEFANI LC, MULLER S, TORRES IL, et al. A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects. *PLoS One* 2013; 8:e74107.
375. EBADI M, GOVITRAPONG P, PHANSUWAN-PUJITO P, et al. Pineal opioid receptors and analgesic action of melatonin. *J Pineal Res* 1998; 24:193-200.
376. SHAVALI S, HO B, GOVITRAPONG P, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. *Brain Res Bull* 2005; 64:471-479.
377. DE ZANETTE SA, VERCELINO R, LASTE G, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. *BMC Pharmacol Toxicol* 2014; 15:40.
378. SCHWERTNER A, DOS SANTOS CCC, COSTA GD, et al. Efficacy of melatonin in the treatment of endometriosis: A phase II, randomized, double-blind, placebo-controlled trial. *Pain* 2013; 154:874-881.
379. SRINIVASAN V, LAUTERBACH EC, HO KY, et al. Melatonin in antinociception: its therapeutic applications. *Curr Neuropharmacol* 2012; 10:167-178.
380. KLENGEL T, PAPE J, BINDER EB, et al. The role of DNA methylation in stress-related psychiatric disorders. *Neuropharmacology* 2014.
381. DUDLEY KJ, LI X, KOBOR MS, et al. Epigenetic mechanisms mediating vulnerability and resilience to psychiatric disorders. *Neurosci Biobehav Rev* 2011; 35:1544-1551.
382. REUL JMHM. Making memories of stressful events: a journey along epigenetic, gene transcription, and signaling pathways. *Front Psychiatry* 2014; 5:5.
383. REUL JMHM, COLLINS A, SALIBA RS, et al. Glucocorticoids, epigenetic control and stress resilience. *Neurobiol Stress* 2015; 1:44-59.
384. TROLLOPE AF, GUTIERREZ-MECINAS M, MIFSUD KR, et al. Stress, epigenetic control of gene expression and memory formation. *Exp Neurol* 2012; 233:3-11.
385. STANKIEWICZ AM, SWIERGIEL AH, LISOWSKI P. Epigenetics of stress adaptations in the brain. *Brain Res Bull* 2013; 98:76-92.
386. MCGOWAN PO. Epigenomic Mechanisms of Early Adversity and HPA Dysfunction: Considerations for PTSD Research. *Front Psychiatry* 2013; 4:110.

387. ZOVKIC IB, SWEATT JD. Epigenetic mechanisms in learned fear: implications for PTSD. *Neuropsychopharmacology* 2013; 38:77-93.
388. ZANNAS AS, PROVENCAL N, BINDER EB. Epigenetics of Posttraumatic Stress Disorder: Current Evidence, Challenges, and Future Directions. *Biol Psychiatry* 2015.
389. GUTIERREZ-MECINAS M, TROLLOPE AF, COLLINS A, et al. Long-lasting behavioral responses to stress involve a direct interaction of glucocorticoid receptors with ERK1/2-MSK1-Elk-1 signaling. *Proc Natl Acad Sci U S A* 2011; 108:13806-13811.
390. SCHMIDT U, HOLSBOER F, REIN T. Epigenetic aspects of posttraumatic stress disorder. *Dis Markers* 2011; 30:77-87.
391. ALMLI LM, STEVENS JS, SMITH AK, et al. A genome-wide identified risk variant for PTSD is a methylation quantitative trait locus and confers decreased cortical activation to fearful faces. *Am J Med Genet B Neuropsychiatr Genet* 2015; 168B:327-336.
392. WINGO AP, ALMLI LM, STEVENS JJ, et al. DICER1 and microRNA regulation in post-traumatic stress disorder with comorbid depression. *Nat Commun* 2015; 6:10106.
393. YEHUDA R, BIERER LM. The relevance of epigenetics to PTSD: implications for the DSM-V. *J Trauma Stress* 2009; 22:427-434.
394. YEHUDA R, DASKALAKIS NP, DESARNAUD F, et al. Epigenetic Biomarkers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Veterans with PTSD. *Front Psychiatry* 2013; 4:118.
395. YEHUDA R, FLORY JD, BIERER LM, et al. Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder. *Biological psychiatry* 2015; 77:356-364.
396. OROZCO-SOLIS R, SASSONE-CORSI P. Epigenetic control and the circadian clock: Linking metabolism to neuronal responses. *Neuroscience* 2014.
397. MASRI S, ZOCCHI L, KATADA S, et al. The circadian clock transcriptional complex: metabolic feedback intersects with epigenetic control. *Ann N Y Acad Sci* 2012; 1264:103-109.
398. STEVENSON TJ, PRENDERGAST BJ. Reversible DNA methylation regulates seasonal photoperiodic time measurement. *Proc Natl Acad Sci U S A* 2013; 110:16651-16656.
399. BELLET MM, SASSONE-CORSI P. Mammalian circadian clock and metabolism - the epigenetic link. *J Cell Sci* 2010; 123:3837-3848.
400. HAIM A, ZUBIDAT AE. Artificial light at night: melatonin as a mediator between the environment and epigenome. *Philos Trans R Soc Lond B Biol Sci* 2015; 370.

401. KORKMAZ A, REITER RJ. Epigenetic regulation: a new research area for melatonin? *J Pineal Res* 2008; 44:41-44.
402. HARDELAND R. Melatonin, noncoding RNAs, messenger RNA stability and epigenetics--evidence, hints, gaps and perspectives. *Int J Mol Sci* 2014; 15:18221-18252.
403. RASTMANESH R. Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. *Med Hypotheses* 2011; 76:79-85.
404. KORKMAZ A, SANCHEZ-BARCELO EJ, TAN DX, et al. Role of melatonin in the epigenetic regulation of breast cancer. *Breast Cancer Res Treat* 2009; 115:13-27.
405. LUI CC, HSU MH, KUO HC, et al. Effects of melatonin on prenatal dexamethasone-induced epigenetic alterations in hippocampal morphology and reelin and glutamic acid decarboxylase 67 levels. *Develop Neurosci* 2015; 37:105-114.
406. SHARMA R, OTTENHOF T, RZECZKOWSKA PA, et al. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. *J Pineal Res* 2008; 45:277-284.
407. JENWITHEESUK A, NOPPARAT C, MUKDA S, et al. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. *Int J Mol Sci* 2014; 15:16848-16884.
408. ZECHEL C. Requirement of retinoic acid receptor isotypes alpha, beta, and gamma during the initial steps of neural differentiation of PCC7 cells. *Mol Endocrinol* 2005; 19:1629-1645.
409. LEON-BLANCO MM, GUERRERO JM, REITER RJ, et al. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. *J Pineal Res* 2003; 35:204-211.
410. SPINHOVEN P, PENNINX BW, VAN HEMERT AM, et al. Comorbidity of PTSD in anxiety and depressive disorders: prevalence and shared risk factors. *Child Abuse Negl* 2014; 38:1320-1330.
411. CALABRESE JR, PRESCOTT M, TAMBURRINO M, et al. PTSD comorbidity and suicidal ideation associated with PTSD within the Ohio Army National Guard. *J Clin Psychiatry* 2011; 72:1072-1078.
412. HARVEY AG. Sleep and circadian functioning: critical mechanisms in the mood disorders? *Annu Rev Clin Psychol* 2011; 7:297-319.
413. MENDLEWICZ J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. *CNS Drugs* 2009; 23 Suppl 2:15-26.
414. MURRAY G, NICHOLAS CL, KLEIMAN J, et al. Nature's clocks and human mood: the circadian system modulates reward motivation. *Emotion* 2009; 9:705-716.



415. MCCLUNG CA. How might circadian rhythms control mood? Let me count the ways. *Biol Psychiatry* 2013; 74:242-249.
416. SCHNELL A, ALBRECHT U, SANDRELLI F. Rhythm and mood: relationships between the circadian clock and mood-related behavior. *Behav Neurosci* 2014; 128:326-343.
417. MCCARTHY MJ, WELSH DK. Cellular circadian clocks in mood disorders. *J Biol Rhythms* 2012; 27:339-352.
418. FINAN PH, QUARTANA PJ, SMITH MT. The Effects of Sleep Continuity Disruption on Positive Mood and Sleep Architecture in Healthy Adults. *Sleep* 2015.
419. SHORT MA, LOUCA M. Sleep deprivation leads to mood deficits in healthy adolescents. *Sleep Med* 2015.
420. PENALVA RG, LANCEL M, FLACHSKAMM C, et al. Effect of sleep and sleep deprivation on serotonergic neurotransmission in the hippocampus: a combined in vivo microdialysis/EEG study in rats. *Eur J Neurosci* 2003; 17:1896-1906.
421. MAGEE JC, CARMIN CN. The relationship between sleep and anxiety in older adults. *Curr Psychiatry Rep* 2010; 12:13-19.
422. MELLMAN TA. Sleep and anxiety disorders. *Psychiatr Clin North Am* 2006; 29:1047-1058; abstract x.
423. SPENCER S, FALCON E, KUMAR J, et al. Circadian genes Period 1 and Period 2 in the nucleus accumbens regulate anxiety-related behavior. *Eur J Neurosci* 2013; 37:242-250.
424. SIPILA T, KANANEN L, GRECO D, et al. An association analysis of circadian genes in anxiety disorders. *Biol Psychiatry* 2010; 67:1163-1170.
425. MONTELEONE P, MAJ M. The circadian basis of mood disorders: recent developments and treatment implications. *Eur Neuropsychopharmacol* 2008; 18:701-711.
426. ASARNOW LD, SOEHNER AM, HARVEY AG. Basic sleep and circadian science as building blocks for behavioral interventions: a translational approach for mood disorders. *Behav Neurosci* 2014; 128:360-370.
427. QUERA SALVA MA, HARTLEY S. Mood disorders, circadian rhythms, melatonin and melatonin agonists. *J Centr Nerv Syst Dis* 2012; 4:15-26.
428. SPADONI G, BEDINI A, RIVARA S, et al. Melatonin receptor agonists: new options for insomnia and depression treatment. *CNS Neurosci Ther* 2011; 17:733-741.
429. HICKIE IB, ROGERS NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. *Lancet* 2011; 378:621-631.

430. TAYLOR D, SPARSHATT A, VARMA S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. *BMJ* 2014; 348:g1888.
431. PAPP M, LITWA E, GRUCA P, et al. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. *Behav Pharmacol* 2006; 17:9-18.
432. LEVITAN MN, PAPELBAUM M, NARDI AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. *Neuropsychiatr Dis Treat* 2015; 11:1149-1155.
433. HANSEN MV, HALLADIN NL, ROSENBERG J, et al. Melatonin for pre- and postoperative anxiety in adults. *Cochr Database System Rev* 2015; 4:CD009861.
434. DANSIE EJ, HEPPNER P, FURBERG H, et al. The Comorbidity of Self-Reported Chronic Fatigue Syndrome, Post-Traumatic Stress Disorder, and Traumatic Symptoms. *Psychosomatics* 2012; 53:250-257.
435. NATER UM, MALONEY E, HEIM C, et al. Cumulative life stress in chronic fatigue syndrome. *Psychiatry Res* 2011; 189:318-320.
436. EGLINTON R, CHUNG MC. The relationship between posttraumatic stress disorder, illness cognitions, defence styles, fatigue severity and psychological well-being in chronic fatigue syndrome. *Psychiatry Res* 2011; 188:245-252.
437. HEIM C, NATER UM, MALONEY E, et al. Childhood Trauma and Risk for Chronic Fatigue Syndrome Association With Neuroendocrine Dysfunction. *Arch Gen Psychiatry* 2009; 66:72-80.
438. HAVILAND MG, MORTON KR, ODA K, et al. Traumatic experiences, major life stressors, and self-reporting a physician-given fibromyalgia diagnosis. *Psychiatry Res* 2010; 177:335-341.
439. DELL'OSSO L, CARMASSI C, CONSOLI G, et al. Lifetime post-traumatic stress symptoms are related to the health-related quality of life and severity of pain/fatigue in patients with fibromyalgia. *Clin Exp Rheumatol* 2011; 29:S73-S78.
440. HAUSER W, GALEK A, ERBSLOH-MOLLER B, et al. Posttraumatic stress disorder in fibromyalgia syndrome: Prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. *Pain* 2013; 154:1216-1223.
441. GALEK A, ERBSLOH-MOLLER B, KOLLNER V, et al. Mental disorders in patients with fibromyalgia syndrome. Screening in centres of different medical specialties. *Schmerz* 2013; 27:296-304.
442. AFARI N, AHUMADA SM, WRIGHT LJ, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. *Psychosom Med* 2014; 76:2-11.

443. BOSCARINO JA, FORSBERG CW, GOLDBERG J. A twin study of the association between PTSD symptoms and rheumatoid arthritis. *Psychosom Med* 2010; 72:481-486.
444. TANRIVERDI F, KARACA Z, UNLUHIZARCI K, et al. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. *Stress* 2007; 10:13-25.
445. KARACA Z, ISMAILOGULLARI S, KORKMAZ S, et al. Obstructive sleep apnoea syndrome is associated with relative hypocortisolemia and decreased hypothalamo-pituitary-adrenal axis response to 1 and 250  $\mu$ g ACTH and glucagon stimulation tests. *Sleep Med* 2013; 14:160-164.
446. ADLER GK, MANFREDSDOTTIR VF, CRESKOFF KW. Neuroendocrine abnormalities in fibromyalgia. *Curr Pain Headache Rep* 2002; 6:289-298.
447. PARKER AJ, WESSELY S, CLEARE AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. *Psychol Med* 2001; 31:1331-1345.
448. LANFRANCO F, MOTTA G, MINETTO MA, et al. Neuroendocrine alterations in obese patients with sleep apnea syndrome. *Int J Endocrinol* 2010; 2010:474518.
449. NIJHOF SL, RUTTEN JM, UITERWAAL CS, et al. The role of hypocortisolism in chronic fatigue syndrome. *Psychoneuroendocrinology* 2014; 42:199-206.
450. MAHDI AA, FATIMA G, DAS SK, et al. Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. *Indian J Biochem Biophys* 2011; 48:82-87.
451. KORSZUN A. Sleep and circadian rhythm disorders in fibromyalgia. *Curr Rheumatol Rep* 2000; 2:124-130.
452. FATIMA G, DAS SK, MAHDI AA, et al. Circadian rhythm of serum cortisol in female patients with fibromyalgia syndrome. *Indian J Clin Biochem* 2013; 28:181-184.
453. FATIMA G, MAHDI AA, DAS SK, et al. Lack of Circadian Pattern of Serum TNF- $\alpha$  and IL-6 in Patients with Fibromyalgia Syndrome. *Indian J Clin Biochem* 2012; 27:340-343.
454. DI GIORGIO A, HUDSON M, JERJES W, et al. 24-hour pituitary and adrenal hormone profiles in chronic fatigue syndrome. *Psychosom Med* 2005; 67:433-440.
455. GIBBS JE, RAY DW. The role of the circadian clock in rheumatoid arthritis. *Arthritis Res Ther* 2013; 15:205.
456. KOURI VP, OLKKONEN J, KAIVOSOJA E, et al. Circadian timekeeping is disturbed in rheumatoid arthritis at molecular level. *PLoS One* 2013; 8:e54049.
457. NATER UM, YOUNGBLOOD LS, JONES JF, et al. Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. *Psychosom Med* 2008; 70:298-305.

458. ZOLI A, LIZZIO MM, FERLISI EM, et al. ACTH, cortisol and prolactin in active rheumatoid arthritis. *Clin Rheumatol* 2002; 21:289-293.
459. YOSHIDA K, HASHIMOTO T, SAKAI Y, et al. Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis. *J Immunol Res* 2014; 2014:282495.
460. SANCHEZ-BARCELO EJ, MEDIAVILLA MD, TAN DX, et al. Clinical uses of melatonin: evaluation of human trials. *Curr Med Chem* 2010; 17:2070-2095.
461. VAN HEUKELOM RO, PRINS JB, SMITS MG, et al. Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion. *Eur J Neurol* 2006; 13:55-60.
462. CITERA G, ARIAS MA, MALDONADO-COCCO JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. *Clin Rheumatol* 2000; 19:9-13.
463. BRUNO A, MICO U, LORUSSO S, et al. Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. *J Clin Psychopharmacol* 2013; 33:507-511.
464. HUSSAIN SA, AL K, II, JASIM NA, et al. Adjuvant use of melatonin for treatment of fibromyalgia. *J Pineal res* 2011; 50:267-271.
465. REITER RJ, ACUNA-CASTROVIEJO D, TAN DX. Melatonin therapy in fibromyalgia. *Curr Pain Headache Rep* 2007; 11:339-342.
466. VIN-RAVIV N, DEKEL R, BARCHANA M, et al. World War II-related post-traumatic stress disorder and breast cancer risk among Israeli women: a case-control study. *Int Psychogeriatr* 2014; 26:499-508.
467. PALESH O, BUTLER LD, KOOPMAN C, et al. Stress history and breast cancer recurrence. *J Psychosom res* 2007; 63:233-239.
468. KELLY-IRVING M, LEPAGE B, DEDIEU D, et al. Childhood adversity as a risk for cancer: findings from the 1958 British birth cohort study. *BMC Public Health* 2013; 13:767.
469. BROWN MJ, THACKER LR, COHEN SA. Association between adverse childhood experiences and diagnosis of cancer. *PLoS One* 2013; 8:e65524.
470. ERREN TC, FALATURI P, REITER RJ. Research into the chronodisruption-cancer theory: the imperative for causal clarification and the danger of causal reductionism. *Neuro Endocrinol Lett* 2010; 31:1-3.
471. SAVVIDIS C, KOUTSILIERIS M. Circadian rhythm disruption in cancer biology. *Mol Med* 2012; 18:1249-1260.
472. LAHTI T, MERIKANTO I, PARTONEN T. Circadian clock disruptions and the risk of cancer. *Ann Med* 2012; 44:847-853.


473. BRIVIO F, FUMAGALLI L, FUMAGALLI G, et al. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. *In Vivo* 2010; 24:239-241.
474. MILLS E, WU P, SEELY D, et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. *J Pineal Res* 2005; 39:360-366.
475. SEELY D, WU P, FRITZ H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. *Integr Cancer Ther* 2012; 11:293-303.
476. CUTANDO A, LOPEZ-VALVERDE A, ARIAS-SANTIAGO S, et al. Role of melatonin in cancer treatment. *Anticancer Res* 2012; 32:2747-2753.
477. REITER RJ. Mechanisms of cancer inhibition by melatonin. *J Pineal Res* 2004; 37:213-214.
478. VIJAYALAXMI, THOMAS CR, JR., REITER RJ, et al. Melatonin: from basic research to cancer treatment clinics. *J Clin Oncol* 2002; 20:2575-2601.
479. WANG J, XIAO X, ZHANG Y, et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. *J Pineal Res* 2012; 53:77-90.
480. LEE SE, KIM SJ, YOON HJ, et al. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. *J Pineal Res* 2013; 54:80-88.
481. KOREN D, ARNON I, LAVIE P, et al. Sleep complaints as early predictors of posttraumatic stress disorder: a 1-year prospective study of injured survivors of motor vehicle accidents. *Am J Psychiatry* 2002; 159:855-857.
482. VAN LIEMPT S. Sleep disturbances and PTSD: a perpetual circle? *Eur J Psychotraumatol* 2012; 3.
483. TICLEA AN, BAJOR LA, OSSER DN. Addressing sleep impairment in treatment guidelines for PTSD. *Am J Psychiatry* 2013; 170:1059.
484. BAJOR LA, TICLEA AN, OSSER DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. *Harv Rev Psychiatry* 2011; 19:240-258.
485. MAYOU RA, BRYANT B. Outcome 3 years after a road traffic accident. *Psychol Med* 2002; 32:671-675.
486. JAKUPCAK M, LUTEREK J, HUNT S, et al. Posttraumatic stress and its relationship to physical health functioning in a sample of Iraq and Afghanistan War veterans seeking postdeployment VA health care. *J Nerv Mental Dis* 2008; 196:425-428.

487. BOSCARINO JA. Diseases among men 20 years after exposure to severe stress: Implications for clinical research and medical care. *Psychosom Med* 1997; 59:605-614.
488. BRESLAU N. Epidemiologic studies of trauma, posttraumatic stress disorder, and other psychiatric disorders. *Can J Psychiatry* 2002; 47:923-929.
489. YAFFE K, VITTINGHOFF E, LINDQUIST K, et al. Posttraumatic stress disorder and risk of dementia among US veterans. *Arch Gen Psychiatry* 2010; 67:608-613.
490. QURESHI SU, PYNE JM, MAGRUDER KM, et al. The link between post-traumatic stress disorder and physical comorbidities: a systematic review. *Psychiatr Q* 2009; 80:87-97.
491. GUPTA MA. Review of somatic symptoms in post-traumatic stress disorder. *Int Rev Psychiatry* 2013; 25:86-99.
492. VANITALLIE TB. Stress: a risk factor for serious illness. *Metabolism* 2002; 51:40-45.
493. BEDI US, ARORA R. Cardiovascular manifestations of posttraumatic stress disorder. *J Natl Med Assoc* 2007; 99:642-649.
494. GORMAN JM, SLOAN RP. Heart rate variability in depressive and anxiety disorders. *Am Heart J* 2000; 140:77-83.
495. BOSCARINO JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. *Ann N Y Acad Sci* 2004; 1032:141-153.
496. POLLACK MH, HOGE EA, WORTHINGTON JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2011; 72:892-897.
497. MARSHALL RD, GARAKANI A. Psychobiology of the acute stress response and its relationship to the psychobiology of post-traumatic stress disorder. *Psychiatr Clin North Am* 2002; 25:385-395.
498. PILORZ V, CUNNINGHAM PS, JACKSON A, et al. A Novel Mechanism Controlling Resetting Speed of the Circadian Clock to Environmental Stimuli. *Curr Biol* 2014.
499. COMAI S, GOBBI G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. *J Psychiatry Neurosci* 2014; 39:6-21.
500. HANSEN MV, DANIELSEN AK, HAGEMAN I, et al. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. *Eur Neuropsychopharmacol* 2014; 24:1719-1728.
501. MALDONADO MD, REITER RJ, PEREZ-SAN-GREGORIO MA. Melatonin as a potential therapeutic agent in psychiatric illness. *Hum Psychopharmacol* 2009; 24:391-400.

502. MALDONADO MD, PEREZ-SAN-GREGORIO MA, REITER RJ. The role of melatonin in the immuno-neuro-psychology of mental disorders. *Recent Pat CND Drug Discov* 2009; 4:61-69.
503. PACCHIEROTTI C, IAPICHINO S, BOSSINI L, et al. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. *Front Neuroendocrinol* 2001; 22:18-32.
504. TAKAHASHI JS, SHIMOMURA K, KUMAR V. Searching for genes underlying behavior: lessons from circadian rhythms. *Science* 2008; 322:909-912.
505. RICHARDS RS, NWOSE EU, BWITITI P. Biochemical basis of circadian rhythms and diseases: With emphasis on post-traumatic stress disorder. *Med Hypotheses* 2011; 77:605-609.

## Figures

**Figure 1. Simplified diagram of pathways modulating melatonin secretion and melatonergic effects.**




**Figure Legend:**

SCN: suprachiasmatic nucleus; PVN: paraventricular nucleus; SCG: superior cervical ganglion; MT1, MT2: melatonin membrane receptors 1 and 2, MT3: quinone-reductase-II; ROR: retinoid orphan nuclear receptors; RZR: retinoid Z nuclear receptors; ROS: reactive oxygen species; RNS: reactive nitrogen species; HPA axis: Hypothalamus-pituitary-adrenal axis. Modified from [10, 18, 25].

**Figure 2. Proposed model of PTSD development: From trauma to sustained chronodisruption.**






**Figure Legend:**

Proposed model of PTSD development. Arrows: temporal order; SAM: sympathoadrenal-medullary system; ANS: autonomic nervous system; HPA-axis: hypothalamus-pituitary-adrenal-axis; GC: glucocorticoid.

**Figure 3. Overview of beneficial melatonergic effects on PTSD-related biological correlates**



### Figure Legend:

Melatonin exerts preventing and restoring/synchronizing effects with beneficial actions on the main PTSD-related biological alterations (red boxes). MLT: melatonin; HPA-axis: hypothalamus-pituitary-adrenal-axis; SAM: sympathoadrenal-medullary system; ANS: autonomic nervous system; GC: glucocorticoid; CGE: circadian gene expression; TBI: traumatic brain injury.